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ABSTRACT 
Pyrimidine derivatives have shown antitubercular, analgesic, anti-inflammatory, antibacterial, 
antimalarial, antifungal, antitumour and anti-HIV activity. There has therefore been an 
increasing number of molecules based on the pyrimidine scaffold that have been synthesised 
in the last decade.  This was done in order to identify lead compounds that could be 
developed and used as pharmaceuticals.   
 
In this work, two types of molecules were synthesised, both of which contained the 
pyrimidine scaffold in their structure.  The first type was 7-amino-5-aryl-6-cyano-5H-
pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-diones (set A and set B) and the second was 5,5'-
(phenylmethylene)bis(6-amino-2-thiouracil) derivatives (set C).  In set A, oxygenated 
derivatives (hydroxy and methoxy) were synthesised and in set B, chloro, nitro and fluoro 
derivatives were synthesised.  Since the oxygenated compounds showed good activity against 
a HeLa cancer cell line, the second set (set B) of pyranopyrimidines with deactivating 
halogens and nitro groups was synthesized.  
 
The 7-amino-5-aryl-6-cyano-5H-pyrano [2,3-d]pyrimidin-(1H,3H)-2,4-diones (A1-7 and B1-
11) were synthesised from substituted aromatic benzaldehydes (ArCHO), malononitrile, 
barbituric acid  and DABCO in  aqueous ethanol in yields of 90-96% in a one pot reaction.  
Compounds A3, A7 and B11 were synthesised for the first time in this work.  Several 
catalysts were also investigated during the optimisation of the reaction including 1,4-
diazabicyclo[2.2.2]octane (DABCO), triethylamine, dibutylamine (DBA), K2CO3 and L-
proline.  Among these, DABCO was found to be the best catalyst, forming the product in 38 
minutes with a yield of 94%.   
xi 
The 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) derivatives (C1-13) were synthesized 
by the condensation of 6-amino-2-thiouracil and benzaldehydes derivatives under reflux in 
glacial acetic acid in yields of 68-96%. Nine compounds (C3, C5 and C7-13) were 
synthesized for the first time in this work.  All compounds were purified either by 
recrystallization or by column chromatography and their structures confirmed by 1D and 2D 
NMR and mass spectroscopy.   
 
All of the derivatives were screened for anti-bacterial activities against five different bacterial 
strains; two Gram-positive strains, Staphylococcus aureus and methicillin resistant 
Staphylococcus aureus (MRSA) as well as three Gram-negative strains, Escherichia coli, 
Pseudomonas aeruginosa and Klebsiella pneumonia. Compound A6 (2',3'-dimethoxy 
derivative) showed broad spectrum activity amongst the strains tested.  In particular, A6 was 
active against S. aureus at 45.6 µM and against E. coli at 91.3 µM.  None of the chloro, 
fluoro and nitro derivatives of 7-amino-5-aryl-6-cyano-5H-pyrano [2,3-d]pyrimidin-(1H,3H)-
2,4-diones (B2-11) showed appreciable antibacterial activity.  The 5,5'-
(phenylmethylene)bis(6-amino-2-thiouracil) derivatives (C1-13) did not show any 
antibacterial activity in preliminary disk diffusion assays.   
 
All the synthesised pyrimidines were also tested for their anticancer activity.  Set A was 
tested against three cell lines, HeLa (cervical cancer cells), Caco-2 (colorectal 
adenocarcinoma cells) and HEK293 (human embryonic kidney cells).  Compounds A2, A5 
and A7 had IC50 values ten times lower (3.46, 4.36 and 4.44 µM) than 5-FU (41.85 µM) in 
the HeLa cell line.  All compounds A1-A7 were comparable (IC50 of 166-297 µM) to 5-FU 
(170 µM) in the Caco-2 cell line and better than 5-FU in the HEK293 cell line (137-333 µM 
as opposed to 505 µM for 5-FU).  The remaining two sets of compounds were tested only 
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against a HeLa cell line, where B1-11 showed comparable activity to 5-FU in the same assay 
and C1-13 showed 3-8 times better activity than 5-FU (IC50 of 10.20-26.02 µM as opposed to 
92.81 µM for 5-FU). 
 
To support our anticancer results, the synthesised compounds were docked computationally 
into the active site of the Eg5 protein (a human kinesin molecular motor protein essential in 
mitosis), which is a therapeutic target for anticancer treatment.  The pyranopyrimidines A1, 
A7, B4 and B8 showed calculated binding energies of -180.25, -140.9, -184.4 and -150.1 kcal 
mol-1, better than 5-FU with a binding energy of -116.7 kcal mol-1 using the same parameters.  
All the 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) derivatives C1-13 were also docked 
into the active site of Eg5 but using an implicit solvent model.  With the exception of C9 (BE 
= -5.0 kcal mol-1), all the compounds showed better binding energies (-12.4 to -26.7 kcal mol-
1) than 5-FU using the same parameters.  In addition, the compounds were seen to form 
hydrogen bonds between their protonated NH groups and CN groups with amino acid 
residues in the protein.  Electrostatic interactions and hydrophobic forces with amino acid 
residues were also observed. 
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Chapter 1. Introduction 
Pyrimidine (1,3-diazine) (1) is a six-membered heterocyclic aromatic organic compound 
containing two nitrogen atoms at positions 1 and 3. The common name pyrimidine was 
approved by the International Union of Pure and Applied Chemistry (IUPAC) for this 
heterocyclic ring system. Several hydro and oxo derivatives of pyrimidine such as 2,4-(1H, 
3H)-pyrimidinedione (2) (uracil), 5-methyluracil (thymine) (3) and 4-aminopyrimidine-2-
(1H)-one (cytosine) (4) are important in biological systems being the nucleotide bases in 
nucleic acids (Loudon and Parise, 2016) (Figure 1-1). Pyrimidines are involved in attaining 
the three-dimensional structure of RNA and DNA (Loudon and Parise, 2016).   
 
 
Figure 1-1  Structures with a pyrimidine nucleus: pyrimidine (1), uracil (2), thymine (3), 
cytosine (4), guanine (5) and adenine (6) 
 
Pyrimidine is a water-soluble, colourless, hygroscopic liquid (m.p. 22.5 °C, b.p. 124 °C) with 
a characteristic odour, similar to pyridine and is rarely found in nature in the free state 
(Verma et al., 2012).  The pyrimidine moiety in biological molecules such as nucleic acids, 
amino acids, vitamins, and their metabolism and biosynthesis is discussed in Lagoja (2005).  
It is a constituent of the purines, guanine (5) and adenine (6) (Loudon and Parise, 2016), 
thiamine (vitamin B1) (7) (Müller et al., 2009), antibiotics such as bacimethrin (8) (Reddick et 
al., 2001), bleomycin (9) (Sugiyama and Kumagai, 2002) and sparsomycin (10) (Wiley and 
MacKellar, 1976) and products of metabolism such as uric acid (11) (Bruice, 2011) and 
toxins such as cylindrospermopsin (12) (Banker et al., 2001) (Figure 1-2). 
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Figure 1-2  Some naturally occurring pyrimidine derivatives 
 
Pyrimidine derivatives have also been known to possess biological activities such as 
antidiabetic (Panahi et al., 2013; Yousefi et al., 2015), antibacterial (Paliwal et al., 2013), 
anti-inflammatory and analgesic (Kadry, 2014), antitumor (Mohamed et al., 2007), 
antimycobacterial (Read et al., 2010), antimalarial (Joshi et al., 2005), and anti HIV (Malik et 
al., 2006). 
 
The pyrimidine scaffold is found in many chemotherapeutic agents.  Sulfadiazine (13) (Oprea 
et al., 2013), trimethoprim (14) (Bushby and Hitchings, 1968) and piritrexim (15) (Kovacs et 
al., 1988) are well known antibiotics with a pyrimidine scaffold (Figure 1-3).  
 
Figure 1-3  Some synthetic pyrimidine chemotherapeutic agents 
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Some pyrimidine derivatives such as the methylsulfonylpiperidine pyrimidine methanone 
(16) (Chu et al., 2006) and tetrasubstituted purine derivatives, for example N-(4-
aminocyclohexyl)-N-(3-chlorophenyl)-9-isopropyl-9H-purine-2,6-diamine (17) (Moravec et 
al., 2003) have been reported as inhibitors of cyclin dependent kinase with significant in vivo 
antitumour activity.  Pyrimidine carboxamides such as compound 18 were shown to have 
anti-inflammatory and anti-immunosuppressive activity (Sullivan et al., 1998), the indole 
thienopyrimidine (19) was shown to have anti-tumour activity  (Munchhof et al., 2004) and 
the pyrazolo thiazolo pyrimidines such as compound 20 were shown to be adenosine enzyme 
inhibitors (Baraldi et al., 2001). 5-Fluorouracil (5-FU) (21) and its derivatives (Figure 1-4), 
were shown to have anticancer activity (Diaso and Harris, 1989; Jain et al., 2006).  5-FU 




Figure 1-4  Structures of pyrimidine compounds with anticancer, anti-inflammatory, anti-
immunosuppressive and CDK and adenosine enzyme inhibition 
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Pyrrolo-pyrimidine nucleoside derivatives such as toyocamycin (22) (Varaprasad et al., 2007) 
and valopicitabine (23) (Coelmont et al., 2006) were shown to act as anti-Hepatitis C (HCV) 
agents and thieno aminopyrimidines such as compound 24 (Figure 1-5) were shown to be 
potent phosphodiesterase (PDE) inhibitors (Crespo et al., 1998).  
 
 
Figure 1-5  Structures of anti-HCV and PDE pyrimidine inhibitors 
 
Zidovudine or azidothymidine (AZT) (25), an anti HIV drug (Darbyshire et al., 2000), the 
general anaesthetic, sodium pentothal (26) (Paul and Harris, 1970), anti-epileptic 
mephobarbital (27) (Aikens et al., 2000), and anti-hypertensive minoxidil (28) (Figure 1-6) 
(Gottlieb et al., 1972) are further examples of drugs containing a pyrimidine scaffold. 
  
 





Pyrano [2,3-d]pyrimidine-2,4-diones consist of an unsaturated N-heterocyclic skeleton 
containing pyran and pyrimidine rings fused together.  They are generally fused in a [2,3-d] 
fashion (Figure 1-7), the "2,3" referring to the position of the fused side in relation to the 
oxygen of the pyran ring and the "d" referring the position of the fused side in relation to the 
pyrimidine ring (Moss, 1998).  The numbering system used for pyrano[2,3-d]pyrimidines and 
pyrano[2,3-d]pyrimidine-2,4(1H,3H)-diones are given in Figure 1-7 below. 
 
 
Figure 1-7  Nomenclature of pyranopyrimidines 
 
Synthesis 
Pyranopyrimidines are synthesised most commonly from aldehydes, barbituric acid and 
malonitrile.  They are also synthesised from arylidene malonitriles and barbituric acid as well 
as several other methods employing other reagents.  These are discussed below. 
 
Pyranopyrimidines from aldehydes, barbituric acid and malonitrile 
Pyrano [2,3-d]pyrimidines are generally synthesized by multicomponent reactions 
(Armstrong et al., 1996). The most common procedure for the preparation of pyrano[2,3-
d]pyrimidine-2,4(1H,3H)-diones is the reaction of barbituric acid or thiobarbituric acid, 
malononitrile and aldehydes (Figure 1-8).  This reaction is usually carried out in a one pot 
reaction under traditional thermal conditions (Heravi et al., 2010; Mobinikhaledi et al., 2010; 
Khurana et al., 2014).  Other conditions under which the reaction is carried out include 
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microwave irradiation, which was done using methylcyanoaceate instead of malonitrile (Bhat 
et al., 2015), ultrasonic irradiation (Yadav and Quraishi, 2014), solvent free (Ziarani et al., 
2013; Khazaei et al., 2015) or catalyst free conditions (Safaei et al., 2012). The catalysts 
employed for these reactions include amino acids such as L-proline (Barjanian et al., 2009) 
and nanocatalysts (Kidwai et al., 2012; Sadeghi et al., 2015). 
 
Figure 1-8  General reaction of pyranopyrimidines synthesis by the three component reaction 
of aldehydes, barbituric acid and malonitrile 
 
The mechanism for the reaction involving malonitrile, aldehydes and barbituric acid is 
discussed in detail in Chapter 3. 
 
Most of the syntheses are carried out using ethanol, water, or a mixture of the two as a 
solvent (Albadi et al., 2014; Maddila et al., 2015; Sadeghi et al., 2015). The reaction time 
varies between 30 minutes to 3 hours  and the yield varies between 72 to 97% depending on 
the type of catalysts used in the reaction (Bararjanian et al., 2009; Mobinikhaledi and Fard, 
2010;  Safaei et al., 2012).   
 
With base catalysts such as 1,4-diazabicyclo[2.2.2]octane (DABCO), dibutylamine (DBA), 
diammonium hydrogen phosphate or Zn[(L) proline]2, the product is formed in less than an 
hour with a yield of 90 percent or more (Balalaie et al., 2008; Heravi et al., 2010; Azizian et 
al., 2012; Jain et al., 2014; Bhat et al., 2014; 2016). When this reaction is performed under 
microwave irradiation the product is formed in less than 7 minutes in catalyst free conditions 
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with yields of 78-94% (Bhat et al., 2015).  Yadav and Quraishi (2014) compared the 
conventional reaction with ultrasonic irradiation  and found that the although the yields were 
still the same under both conditions (42-98%), the duration of the reaction was slightly 
shorter for ultrasound irradiation (for example, <2 minutes as opposed to 5 minutes). They 
also found that triethanolamine is a good, cost effective base and that ethanol is a good 
solvent for the reaction.   
 
Ziarani et al. (2013) made use of a SBA-Pr-SO3H nanocatalyst without a solvent to produce 
pyranopyrimidines in yields of between 30-90% in 45 minutes or less, whilst  Khazaei et al. 
(2015) used a ZnFe2O4 nanocatalyst to achieve yields of 86-96% in under 30 minutes, also 
under solvent free conditions. Pyranopyridimidines were also formed under catalyst free 
conditions using glycerol as a solvent in yields of 90-95% in reaction times of between one to 
three and a half hours (Safaei et al., 2012).   
 
Pyranopyrimidines from arylidinemalonitriles and barbituric acid 
Another common method for forming pyranopyrimidines involves reacting 
arylidenemalonitriles with barbituric acid or thiobarbituric acid (Figure 1-9). 
 
 
Figure 1-9  General reaction of pyranopyrimidines synthesised by a two component reaction 
of arylidenemalonitrile and barbituric acid 
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These reactions were carried out under reflux for 3 hours using triethylamine with ethanol 
resulting in yields of 80% and above (Aly and Kamal, 2012).  They were also formed by 
dissolving the two components in ionic liquids and heating them to 90 ºC for 3 hours (Yu and 
Wang, 2005).  Here, the pyridine and imidazole ionic liquids acted as a solvent and catalyst 
in one.  Instead of conventional heating and reflux conditions, these reactions were also 
successful under microwave conditions in 3-5 minutes, producing excellent yields of between 
86-94% (Gao et al., 2004). 
 
Miscellaneous methods 
Pyranopyrimidines were also formed by reacting aldehydes, malonitrile and ethyl 
acetoacetate to first form 2-amino-4-phenyl-4H-chromen-3-carbonitrile derivatives, which 
are subsequently converted to pyranopyrimidines in yields of between 50-90% by cyclising 
them with acetic anhydrides in the presence of a silica sulphuric acid catalyst for 1-3 hours 
(Figure 1-10) (El-Bayouki et al., 2013) or under reflux in acetic anhydride with a catalytic 
amount of concentrated sulphuric acid (Shahi et al., 2015).  A base catalyst was not needed 
for this reaction as discovered by Litvinov and Shestopalov (2008), who obtained a tar like 
substance when heating the 6-methyl-5-carboxylate derivative of 2-amino-4-phenyl-4H-
chromen-3-carbonitriles with piperidine, but obtained the pyranopyrimidine without the base 
catalyst in 10 hours with a yield of 51%.  On the contrary, catalytic amounts of sulfuric acid 





Figure 1-10  Pyranopyrimidines from 2-amino-4-phenyl-4H-chromen-3-carbonitrile 
derivatives and acetic anhydride 
 
Quintela et al. (1995) used arylidenemalonitriles to form 2-amino-4-phenyl-4H-chromen-3-
carbonitriles with ethyl acetoacetate and then convert these products with a phosgeneiminium 
salt in 1,2-dichloroethane under reflux for 1 hour followed by passing through a stream of dry 




Figure 1-11  Conversion of 2-amino-4-phenyl-4H-chromen-3-carbonitriles with a 
phosgeneiminium salt and dry HCl 
 
Abd El-Wahab et al. (2012) first formed 2-amino-3-cyano-4-arylnaphthopyrans from 
arylidene malonitriles and 6-methoxy-2-naphthol to produce 2-amino-3-cyano-4-
arylnaphthopyran derivatives, which were then converted to three different pyranopyrimidine 




Figure 1-12  Synthesis of three different pyranopyrimidines from 2-amino-3-cyano-4-
arylnaphtho-4H-pyrans using various reagents 
 
The 2-amino-4-aryl-3-cyano-4H-pyran intermediates were also converted to 
pyranopyrimidines using N,N-dimethylacetaldehyde dimethyl acetal and aromatic amines in 
the presence of an imidazole ionic liquid to produce pyranopyrimidines in 87-94% yield in 2-
4 hours at 80 ºC (Figure 1-13) (Suresh et al., 2015).  
 
 
Figure 1-13  Synthesis of pyranopyrimidines using N,N-dimethylacetaldehyde dimethyl 
acetal, aromatic amines in an ionic liquid 
 
When the 2-amino-4-phenyl-4H-chromen-3-carbonitrile derivatives were first treated with 
triethyl orthoformate, they converted the primary amino group to an ethoxymethyleneimino 
group, which was subsequently cyclised to imino pyranopyrimidines in 76% yield with 
hydrazine hydrate in ethanol in 45 minutes (Figure 1-14) (El-Agrody et al., 2001).  A similar 
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reaction was used to synthesise pyrazolopyranopyrimidines from pyrazolo 4-aryl-3-cyano-2-
ethoxymethyleneimino-4H-pyran derivatives (El-Assiery et al., 2004). 
 
 
Figure 1-14  Synthesis of pyranopyrimidines from 2-ethoxymethyleneimino-4-phenyl-4H-
chromen-3-carbonitrile derivatives 
 
β-aroylacrylic acids were first converted to 4-carboxyl-2-ethoxymethyleneimino-4H-
chromene-3-carbonitrile derivatives using either malonitrile and ammonium acetate or 
malonitrile and piperidine.  This intermediate was then converted to various 
pyranopyrimidines using sodium hydrogen sulphide, hydrazine, phenylhydrazine, ammonia 
and alkyl and aryl amines (Figure 1-15) (El-Hashash et al., 2009). 
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Figure 1-15  The synthesis of pyranopyrimidines from 4-carboxyl-2-ethoxymethyleneimino-
4H-chromene-3-carbonitrile derivatives using various reagents 
 
Chalcones and barbituric acids were shown to produce pyranopyrimidines in the presence of 
phosphorus pentoxide and acetic acid under reflux at 135-140 ºC for 6-8.5 hours in yields of 
52-86% (Figure 1-16) (Rahman et al., 2013). 
 
 
Figure 1-16  Synthesis of pyranopyrimidines from chalcones and barbituric acid 
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Yousefi et al. (2015) used curcumin instead of malonitrile together with barbituric acid and 
aldehdyes to form pyranopyrimidine derivatives in yields of between 80-87% using a para-
toluene sulphonic acid catalyst (PTSA) under reflux in ethanol for 8 hours (Figure 1-17). 
 
 
Figure 1-17  Synthesis of curcumin derivatives of pyranopyrimidine 
 
Tetrahydro-2H-pyran-2-one was used  instead of barbituric acid with different nitriles in the 
presence of trifluoromethanesulfonic anhydride to produce 2,4 disubstituted 6,7-dihydro-5H-
pyrano[2,3-d]pyrimidines  (Figure 1-18) (Herrera et al., 2006). The reagents were cooled to -
78 ºC, added and stirred at º0 C for 4 days to produce yields of 40-90%.   
 
 
Figure 1-18  Synthesis of pyranopyrimidines from tetrahydro-2H-pyran-2-one derivatives 
and acetonitriles 
 
A mixture of 5-ethoxycarbonyl-2H-pyran-2-one, substituted amidine hydrochlorides and 
DBU (as a base) in ethanol produced the corresponding pyranopyrimidine under microwave 
irradiation in 120 minutes at 110 ºC in yields of 56% (Hren et al., 2009).  Under the same 
conditions, but with sodium carbonate as a base, the didehydro amino acid derivatives could 
be prepared, which could be converted to the corresponding pyranopyrimidines in 92% yield.  
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Thus, the two step reaction resulted in better yields (78% overall) than the 56% yield in the 
one step reaction (Figure 1-19) (Hren et al., 2009). 
 
 
Figure 1-19  Synthesis of pyranopyrimidine from 5-ethoxycarbonyl-2H-pyran-2-one under 
microwave conditions 
 
Pyranopyrimidines were also formed in yields of 56-63% by the reaction of 5-formyl-6-
hydroxyuracils and Meldrum's acid with a catalytic amount of piperidine in ethanol under 
reflux for 20 hours (Figure 1-20) (Deb and Bhuyan, 2006). 
 
 
Figure 1-20  Synthesis of pyranopyrimidines from 5-formyl-6-hydroxyuracils and Meldrum's 
acid 
 
The same starting material (5-formyl-6-hydroxyuracil) also formed pyranopyrimidines with 
maleimide or phenylisocyanate under microwave conditions at 120 ºC for 5 minutes, 




Figure 1-21  Pyranopyrimidines from 5-formyl-6-hydroxyuracil and either maleimide or 
phenylisocyanate 
 
Kidwai et al. (2000) reported the synthesis of functionalized pyrano[2,3-d]pyrimidines from 
1,3-diarylthiobarbituric acids, hippuric acid and triethylorthoacetate on basic alumina in 
ethanol under microwave conditions for 1 minute, which yielded the products in yields of 92-
95% (Figure 1-22).   
 
 
Figure 1-22  Pyranopyrimidines synthesised from thiobarbituric acid, hippuric acid and 
triethylorthoacetate 
 
1.2  5,5'-(Phenylmethylene)bis(6-amino-2-thiouracil) derivatives 
5,5'-(Phenylmethylene)bis(6-amino-2-thiouracil) consists of two 6-amino-2-thiouracil units, a 
phenyl unit and a hydrogen atom all attached to a central carbon atom (Figure 1-23).   
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Figure 1-23  The basic structure of 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) 
derivatives 
 
The first reported synthesis of 6-amino-2-thiouracil with formaldehyde was reported by 
Pfleiderer et al. (1966) (Figure 1-24).  The mechanism for this reaction is discussed in detail 
in Chapter 4. 
 
 
Figure 1-24  The first reported reaction of 6-amino-1-methyl-2-thiouracil 
 
Chebanov et al. (2005) prepared the methyl, chloro and fluoro phenyl derivatives of 5,5'-
(phenylmethylene)bis(6-amino-2-thiouracil) derivatives whilst trying to find alternate 
methods to form pyrido[2,3-d]pyrimidine derivatives. Instead of reacting 6-amino-2-
thiouracil with chalcones, he reacted them with chalcone precursors of acetophenone and 
benzaldehyde.  To their surprise, the reaction proceeded without the participation of 
acetophenone and formed 5,5'-(phenylmethylene)bis(6-amino-2-thiouracils) (Figure 1-25). 
17 
 
Figure 1-25  Reaction of 6-amino-2-thiouracils with para substituted benzaldehydes 
 
6-Amino-1-methyl-2-thiouracil reacted with aromatic aldehydes in absolute ethanol in the 
presence of HCl at room temperature for one and a half hours or glacial acetic acid under 
reflux for 1 hour to produce 5,5'-(phenylmethylene)bis(6-amino-1-methyl-2-thiouracil) 
derivatives (Figure 1-26) (El-kalyoubi et al., 2015).  The duration of the reflux is critical as 
they achieved pyrido[2,3-d]pyrimidines upon refluxing for 4-6 hours.  Consequently, 
refluxing the bis compounds for 1 hour in an equal mixture of acetic acid and HCl also 
resulted in pyrido[2,3-d]pyrimidines. 
 




Youssif et al. (2003) reported a similar reaction with 6-amino-2-thiouracil and formalin in 
ethanol under reflux for 4 hours forming the bis products.  Upon heating these bis products 
under reflux with acetic acid and a catalytic amount of HCl, pyridodipyrimidines were 
formed (Figure 1-27).  In 2008, Youssif and Mohamed repeated the reaction, but with 
substituted benzaldehydes, where the bis (6-amino-2-thiouracils) were formed in 1.5-2.5 
hours at room temperature, but the pyridopyrimidines were formed in 2-7 hours under reflux 
(Youssif and Mohamed, 2008). 
 
 
Figure 1-27  Synthesis of methylene bis(6-amino-2-thiouracil) and its conversion to 
pyridopyrimidines 
 
To the best of our knowledge, 5,5'-(phenylmethylene)bis(6-amino-2-thiouracils) have not 
been extensively tested for their bioactivity. El-Khayoubi et al. (2015), tested several 
derivatives for anitviral and antibacterial activity.  Only the para fluoro derivative (Figure 
1-28) showed broad spectrum antibacterial activity.  None of the other compounds tested 
showed appreciable antibacterial activity.  They also showed poor antiviral activity in the 
same study.  Youssif et al. (2008) also reported poor antimicrobial activity of the 5,5'-





Figure 1-28  5,'5-(4-phenylmethylene)bis(6-amino-2-thiouracil) showing broad spectrum 
antibacterial activity 
 
Although not much biological studies were carried out on 5,5'-(phenylmethylene)bis(6-
amino-2-thiouracils), there have been biological studies on other 6-amino-2-thiouracil 
derivatives. 
 
S-benzylated analogues of pyrimidine-4-ones, structurally similar to the 6-amino-2-
thiouracils (Figure 1-29) (El-Moghazy et al., 2011), the pyrrolopyrido 2-thiouracil derivative 
(Figure 1-30) (Gomha et al., 2014) and some benzenesulfonamide derivatives of 6-amino-2-
thiouracil (Figure 1-31) (Awad et al., 2015) have shown promising anticancer activity. 
 








Figure 1-31  Some benzenesulfonamide derivatives of 6-amino-2-thiouracil with promising 
anticancer activity 
 
1.3 Hypothesis  
It is hypothesized that since pyrimidine derivatives have found application in a wide variety 
of pharmaceutical applications, including anticancer and antibacterial activity, novel 




The main aim of this project is to synthesise two small libraries of pyrimidine molecules and 
test them for their anticancer and antibacterial activity in order to identify lead compounds, 
which could be developed further into anticancer and antibacterial agents. 
 
Specific aims 
1.   To synthesise two classes of pyrimidine derivatives, which vary at one point in their 
scaffold. 
2.   To characterize the synthesised compounds using NMR and Mass spectroscopy to verify 
that these compounds had indeed been formed. 
3.   To test the synthesised compounds for their anticancer activity. 
4.   To test the synthesised compounds for their antibacterial activity. 
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Chapter 2. Synthesis, characterization, anticancer and antibacterial 
activity of some novel pyrano[2,3-d]pyrimidinone carbonitrile 
derivatives  
* The compounds referred to in this chapter are referred to in the abstract, conclusion and appendices or 
elsewhere in the thesis with an A preceding the number of the compound.  For example, 1 and 2 are referred to 
as A1 and A2 elsewhere in the thesis. 
 
ABSTRACT 
A series of oxygenated substituted 7-amino-5-aryl-6-cyano-5H-pyrano pyrimidin-2,4-dione 
derivatives were synthesized in a one-pot reaction by reacting malononitrile and barbituric 
acid with several aromatic aldehydes in the presence of 1,4-diazabicyclo[2.2.2]octane 
(DABCO) in aqueous medium to produce the title compounds.  The 3,4-dihydroxyaryl (3) 
and the 2,5-dimethoxy (7) derivatives were novel.  The structures of the synthesized 
compounds were elucidated by means of 1H, 13C and 2D NMR spectroscopy.  Compounds 3 
(3',4'-dihydroxy derivative), 5 (4'-methoxy derivative) and 6 (2',3'-dimethoxy derivative) 
showed antibacterial activity comparable to or better than the standard ampicillin.   
Compound 6 is an excellent candidate for a broad spectrum antibiotic with MBCs up to five 
times better (45.6-365.2 µM) than ampicillin, while both 3 and 6 have the potential to be 
developed into an antibiotic against MRSA, with MBCs of 183-199 µM, five times better 
than ampicillin.  All the test compounds 1-7 showed good anticancer activity.  The IC50 values 
ranged from 3.46 to 37.13 µM (HeLa); 136.78 to 297.05 µM (Caco-2) and 137.84 to 333.81 
µM (HEK293).  The best activity was seen in the HeLa cell line when compared to the 
standard 5FU (5-Fluorouracil IC50 of 41.85 µM), with 1, 2, 5 and 7 having IC50 values of 10.64, 
3.46, 4.36 and 4.44 µM respectively.  Additionally, two representative compounds (1 and 7) 
found to be potent against the two cell lines (HeLa and HEK 293) were docked into the 
binding site of human kinesin Eg5 with the aim of predicting their binding propensities and to 
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establish their mechanism of action.  This one pot reaction is carried out in aqueous ethanol 
and therefore the procedure is considered green.  The reaction occurs under mild conditions 
producing high yields of products.  
 




The heterocyclic 7-amino-5-aryl-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-diones are 
annelated pyrimidine derivatives, containing pyrimidine, pyrano and aryl functionalities 
within a single molecule.  Pyrimidines have widespread pharmacological activity such as 
anticancer (Babu et al., 2004), antiviral (Chern et al., 2004), antimalarial (Joshi et al., 2005) 
and antibacterial properties (Mishra et al., 2008) and therefore synthesis of molecules 
containing pyrimidine in its core structure is always of interest.   
 
The 7-amino-5-aryl-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-diones have been 
previously synthesised under microwave conditions without a catalyst from arylidene 
malonitrile and barbituric acid (3-5 minutes) (Gao et al., 2004) and from benzaldehydes, alkyl 
nitriles and barbituric acid (4-8 minutes) (Devi et al., 2003).  Various catalysts such as 
diammonium hydrogen phosphate (Balalaie et al., 2008), Zn[(L) proline]2 (Heravi et al., 
2010) and a nanoporous SBA-Pr-SO3H nanocatalyst (Ziarini et al., 2013) were also used to 
synthesise these compounds from benzaldehydes, malonitrile and barbituric acid in good 
yields.  The reaction was also carried out with arylidene malonitrile and barbituric acid 
dissolved in ionic liquids (Yu and Wang, 2005).  Triethylamine was used to catalyse the 
reaction of 2-thioxodihydropyrimidin-4,6(1H,5H)-dione (instead of barbituric acid) with 
benzylidene malonitrile to synthesise 2-thioxo derivatives of these compounds (Aly et al., 
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2012).  Other potential catalysts for this reaction are salts of Li, which although not used to 
synthesise these molecules, have been used to catalyse the synthesis of chromene derivatives 
from benzaldehydes, nitriles and a cyclic 1,3-dicarbonyl compound (Sun et al., 2010). 
 
In this work, we have used DABCO (1,4-diazabicyclo[2.2.2]octane), reported to be a mild 
and efficient catalytic system for the synthesis of pyrano[2,3-d]pyrimidinones in good yields 
(Jain et al., 2014; Bhat et al., 2014) to synthesise a small library of 7-amino-5-aryl-6-cyano-
5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-diones and test them for their antibacterial and 
anticancer activity. 
 
2.2 Results and Discussion 
Chemistry 
The title compounds were synthesized in a one pot reaction from substituted aromatic 
benzaldehydes (ArCHO), malononitrile, barbituric acid and DABCO (10% mol ratio) in  
aqueous ethanol (Figure 2-1) to produce 7-amino-5-aryl-6-cyano-5H-pyrano[2,3-
d]pyrimidin-(1H,3H)-2,4-diones (1-7) in yields of between 90-96%.  The structures of the 
products were confirmed from their 1H and 13C NMR spectra (Table 2-1 and Table 2-2) and 
the resonances assigned with the aid of 2D HSQC and HMBC spectra.  We have chosen 
oxygenated derivatives such as hydroxy and methoxy derivatives to investigate the effect 
these moieties have on the pyrano[2,3-d]pyrimidinones in anticancer and antibacterial assays. 
 
The reaction occurs via proton removal from the methylene group of malonitrile, which 
subsequently forms an arylidene derivative with substituted benzaldehydes via a 
Knoevenagel condensation.  This arylidene derivative then undergoes a Michael reaction with 
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barbituric acid and subsequent cyclisation results in the pyrano[2,3-d]pyrimidinones (Kaupp 
et al., 2003). 
 
 
Figure 2-1  DABCO catalyzed reaction of pyrano pyrimidine derivatives (1-7) 
 
Table 2-1  1H NMR data of 7-amino-5-aryl-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-
2,4-diones in DMSO-d6 (400 MHz) 
Pos. 1 2 3 4 5 6 7 
           5 4.26 s 4.11 s 4.01 s 4.20 s 4.16 s 4.47 s 4.42 s 
          NH-1 12.07br  s 12.04 br s 11.94 s 12.04 s 12.00 br s 11.97 br s 11.98 br s 
 NH-3 11.08 s 11.05 s 11.04 s 11.05 s 11.02 s 10.97 s 10.99 s 
          NH2-11  7.14 s 7.03-7.07 7.01 s 7.08 s 7.04 s 6.98 s 6.95 s 
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Table 2-2  13C NMR data of 7-amino-5-aryl-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-
2,4-diones in DMSO-d6 (100 MHz) 
Pos. 1 2 3 4 5 6 7 
2 149.4 149.5 149.6 149.8 149.4 149.5 149.5 
4 162.4 162.4 162.4 162.4 162.4 162.3 162.4 
5 35.6 35.5 34.8 35.6 34.8 30.7 31.1 
6 58.7 58.9 59.6 58.6 59.1 58.3 57.7 
7 157.7 157.6 157.6 157.6 157.5 157.9 158.2 
8 152.4 152.2 152.0 152.7 152.0 152.2 153.0 
9 88.5 88.6 89.4 88.3 88.7 88.4 87.6 
10 119.1 119.2 119.5 119.1 119.2 119.2 119.2 
1' 144.2 145.6 135.2 145.9 136.2 136.8 132.8 
2' 129.4 113.7 114.6 113.7 128.3 146.5 151.4 
3' 128.2 157.2 145.1 159.2 113.6 152.4 112.9 
4' 127.4 113.9 144.2 112.0 158.0 111.3 111.6 
5' 128.2 129.2 115.4 129.2 113.6 123.5 152.7 
6' 129.4 117.8 118.0 119.3 128.3 120.8 115.3 










In order to identify the best catalyst for the reaction, five basic catalysts were used 
independently under reflux conditions at 80 ºC with equimolar quantities of benzaldehyde, 
malonitrile and barbituric acid in a mixture of 1:1 ethanol and water to identify the catalyst 
that produced the greatest yield in the shortest time.  The catalysts investigated were L-
proline, K2CO3, dibutylamine (DBA), triethylamine (Et3N) and 1,4-diazabicyclo[2.2.2]octane 
(DABCO).  Of these, DBA, Et3N and DABCO resulted in yields of over 70% in 
approximately one hour (Table 2-3).   DABCO performed the best, producing yields of 94% 
in 38 minutes. 
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Table 2-3  The effect of different catalysts under optimized reaction conditionsa 
Catalyst Time (mins) Yield % 
No catalyst 1080 (18h) 5 
L-Proline 180 (3h) 45 
K2CO3 110 57 
DBAb 54 74 
Et3N 70 81 
DABCOc 38 94 
aReaction conditions: barbituric acid (1 mmol), benzaldehyde (1 mmol), malononitrile (1.1 mmol) and 
EtOH:water (1:1 v/v, 10 mL), R.T; bdibutylamine; c1,4-diazabicyclo[2.2.2]octane 
 
The 1H and 13C NMR spectra were similar for all seven compounds and the only difference in 
the spectra were brought about by differences in the aryl moiety of the molecule substituted 
at C-5.  Using compound 1 (the pyrimidine with the unsubstituted aryl ring) as an example, a 
characteristic H-5 resonance was seen as a singlet at δ 4.26, which was an indication that the 
pyrimidines had formed.  Due to the lack of protonated carbons on the core pyrimidine 
skeleton, the only other proton indicators were the protons on the 1º and 2º nitrogen atoms.  
NH2-11 occurred as a two proton singlet together with the aromatic protons at δ 7.14, NH-1 
occurred as a singlet at δ 11.08 and NH-2 occurred as a broadened singlet at δ 12.07.  The 
aromatic resonances occurred as a three-proton and two proton multiplet at δ 7.18-7.22 (H-
2'/4'/6') and δ 7.29-7.32 (H-3'/5'). 
 
For 2 (3'-hydroxy derivative), H-2'/4'/6' occurred as a three-proton multiplet at δ 6.54-6.61 
and H-5' overlapped at δ 7.03-7.07 with NH2-11 as a multiplet.  The 3',4'-dihydroxy 
derivative (3) showed the presence of two doublets and a double doublet for H-5', H-2' and 
H-6' at δ 6.62 (J = 8.1 Hz), δ 6.55 (J = 2.0 Hz) and δ 6.45 (J = 8.1, 2.0 Hz) respectively.  In 
the 3'-methoxy derivative (4), the H-5' double doublet occurred as a triplet due to the same 
coupling constants at δ 7.20 (J = 7.9, 7.9 Hz) downfield from the other three aromatic proton 
resonances, which occurred at δ 6.72-6.76 as a multiplet.  The 3'-OCH3 resonance appeared 
as an intense singlet at δ 3.72.  In compound 5, the phenyl ring at C-5 was para disubstituted 
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with a methoxy group at C-4'.  This methoxy group was seen at δ 3.72 as a singlet.  A pair of 
doublets at δ 7.10 and δ 6.83, each with J = 8.6 Hz, were assigned to H-2'/6' and H-3'/5' 
respectively.  These assignments were made due to H-3'/5' being more electron dense than H-
2'/6' due to resonance electron donation from the methoxy group and was confirmed by an 
HMBC correlation from H-2'/6' to C-5. 
 
In the 2',3'-dimethoxy derivative (6), H-5' partially overlaps with H-11, but can still be 
observed as a double doublet (appearing as triplet) at δ 6.95 (J = 7.6, 7.6 Hz) and H-4' and H-
5' are observed as a doublet and double doublet at δ 6.87 (J = 7.6 Hz) and δ 6.65 (J = 7.6, 1.2 
Hz) respectively.  The 2'-methoxy resonance was assigned to δ 3.72 since it shows an HMBC 
correlation to C-2', which in turn was identified by an HMBC correlation to H-5.  The 3'-
methoxy group was present at δ 3.77.  In the 2',5'-dimethoxy derivative (7), H-3' and H-6' 
occurred as doublets at δ 6.89 (J = 8.9 Hz) and δ 6.59 (J = 3.1 Hz) respectively and H-4' 
occurred as a double doublet at δ 6.75 (J = 8.9, 3.1 Hz).  The two methoxy group resonances 
were present at δ 3.68 (2'-OCH3) and δ 3.66 (5'-OCH3) and were identified in a similar 
manner to 6.  C-2' showed a HMBC correlation to both H-5 and the 2'-OCH3 resonance. 
 
The 13C NMR spectrum of the 7-amino-5-aryl-6-cyano-5H-pyrano[2,3-d]pyrimidin-2,4-dione 
core has characteristic carbon resonances.  There are five downfield carbon resonances at δ 
162.4 (C-4), 157.7 (C-7), 152.4 (C-8), 149.4 (C-2) and 144.2 (C-1'), which consisted of the 
two carbonyl groups, the two olefinic C-O resonances and the fully substituted aromatic 
carbon (C-1') of the phenyl ring.  Four other characteristic carbon resonances, consisting of 
the carbonitrile carbon (C-10, δ 119.1), the olefinic carbon on the pyrimidine ring (C-9, δ 
88.5), the olefinic carbon attached to the nitrile group (C-6, δ 58.7) and the methine carbon 
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on the pyran ring (C-5, δ 35.6) resonated more upfield.  The HMBC correlations of the H-5 
proton resonance were instrumental in assigning the carbon resonances in the core structure 
(Figure 2-2).  H-5 showed HMBC correlations to C-8, C-9 and C-4 of the pyrimidine ring, 
C-6 and C-7 of the pyran ring, C-1', C-2' and C-6' of the phenyl ring and the cyano carbon C-
10.  The C-7 carbon resonance at δ 157.7 was distinguished from C-4 and C-8 due to an 
HMBC correlation to the NH2 proton resonance at δ 7.14.  For the 2' substituted 
pyrimidinones 6 (2',3'-dimethoxy) and 7 (2',5'-dimethoxy), a HMBC correlation from H-5 to 
C-2' and then from C-2' to the 2'-OCH3 proton resonance was used to assign the methoxy 




Figure 2-2  HMBC correlations from H-5 to the surrounding carbon atoms in 1 
 
Antibacterial activity 
Compounds 3, 5 and 6 showed promising antibacterial activity from preliminary disc 
diffusion assays and were selected to determine their MBC values using the broth 
microdilution method.  They were tested against the Gram positive Staphylococcus aureus  
ATCC 25923 and methicillin resistant Staphylococcus aureus ATCC BAA-1683 (MRSA) as 
well as three Gram negative strains, Escherichia coli ATCC 25922, Pseudomonas aeruginosa 
ATCC 27853 and Klebsiella pneumonia ATCC 31488.  Compound 6 showed excellent 
activity showing fivefold better activity than ampicillin against MRSA (at 183 µM) and E. 
coli (91.3 µM) and 2.5 fold better activity than K. pneumonia (183 µM) (Table 2-4).  
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Compound 3 also showed excellent activity against MRSA at 199 µM and the activity of 5 
was twofold higher than that of ampicillin (100 µM). 
 
These results show that compound 6 is a potential broad spectrum antibiotic since it shows 
better activity than ampicillin and excellent activity against Gram negative bacteria.  
Compound 3 can also be considered a lead compound to be developed into an antibiotic 
against MRSA and 5 a potential antibiotic for Staphylococcal infections. 
 
Table 2-4  Minimum bactericidal concentration (MBC in µM) of 3, 5 and 6 
Bacterial strains 3 5 6 Ampa  Cipb  
S. aureus 398 100 45.6 55.9 1.84 
MRSA 199 801 183 894 7.36 
E. coli 1591 801 91.3 447 1.84 
P. aeruginosa 1591 400 365.2 1788 1.84 
K. pneumoniae 796 801 183 447 1.84 
aampicillin; bciprofloxacin 
Anticancer activity 
The in vitro cytotoxicity levels of compounds 1-7 in the three cell lines, viz. HeLa, Caco-2 
and HEK293 are summarized in Table 2-5, which shows the IC50 values of the 7 compounds.  
These IC50 values were calculated from experiments carried out at concentrations ranging 
from 10-100 µg mL-1. All results show that almost all compounds were active from the 
lowest concentration tested (10 µg mL-1).  The IC50 values ranged from 3.46 to 37.13 µM in 
the HeLa cells; 136.78 to 297.05 µM in the Caco-2 cells and 137.84 to 333.81 µM in the 
HEK293 cells. A typical dose dependent cytotoxicity was seen in the Caco-2 and HEK293 
cells. The levels of cytotoxicity of all seven compounds were very similar to that of the 
standard 5FU, however in comparison to the standard drug 5FU (IC50 of 41.85 µM) in the 
HeLa cells, compounds 2, 5 and 7  were ten times more active with IC50 values of 3.46, 4.36 
and 4.44 µM respectively. There was no real trend between the position and nature of the 
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substituent on the aromatic ring in relation to the activity.  Compound 2 has a meta hydroxy 
group, compound 5 has a para methoxy group and compound 7 has methoxy groups at the 
ortho and meta positions (2' and 5').  The activity of these compounds could be specific to 
these substituents at those particular positions on the aromatic rings as changing these 
positions (compound 6 vs compound 7 and compound 4 vs compound 5) resulted in 
decreased activity. 
Compound 1 was also quite active with an IC50 of 10.64 µM.  This is considerably lower than 
that of the standard cancer drug (5FU), suggesting that these compounds are active at a much 
lower dose which indicates potential for future use as possible anti-cancer agents. However, 
this does not discount the other compounds (3, 4 and 6) tested which also produced lower 
IC50 values.  In the Caco-2 cells, although all 7 compounds had IC50 values higher than that of 
5FU, they still produced significant cytotoxicity with compound 3 containing hydroxy groups 
at the meta and para positions, eliciting the most activity. In the case of the normal cell line 
HEK293, there was reduced cytotoxicity levels compared to that in the cancer cell lines 
suggesting cell specific cytotoxicity.  The methoxy compounds 5 (4'-OCH3) and 6 (2',3'-
diOCH3) least affected the HEK293 cells and should be more closely examined in future 
studies. Further optimization and testing of all compounds are hence warranted. 
Table 2-5  In vitro cytotoxic effect of synthesized compounds 1-7 (IC50 µM) 
No HeLa Caco-2 HEK293 
1 10.64±0.02b 166.28±0.03b 193.97±0.02c 
2 3.46±0.01a 287.42±0.03g 243.59±0.02d 
3 26. 02±0.0d 136.78±0.02a 177.42±0.02b 
4 20.35±0.07c 175.13±0.02d 184.23±0.02b 
5 4.36±0.07a 185.45±0.01e 333.81±0.01e 
6 37.13±0.05e 297.05±0.01h 293.80±0.02e 
7 4.44±0.05a 235.00±0.02f 137.84±0.02a 
5FU* 41.85±0.06f 170.77±0.2c 505.15±0.02f 
*5-Fluorouracil 
Data are presented as the mean ± SD values of triplicate determinations. a-f Different superscript letters for a 
given value within a column are significantly different from each other (Tukey’s-HSD multiple range post hoc 
test, p < 0.05), ND, Not determined. 
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Computational results 
Human kinesin, Eg5 is an important target protein for the design of new anti-cancer agents 
owing to its overexpression in various cancers such as breast, uterus, ovary and lung cancer 
(Garcia-Saez et al., 2007). Several pyrimidine scaffolds inhibiting Eg5 are reported in the 
literature (Yan et al., 2004).  This motivated us to assess the tendency of our synthesized 
compounds to inhibit this enzyme with the aim of establishing the mechanism for their anti-
cancer activity observed under in vitro conditions. First, the X-ray structure of Eg5 co-
crystallized with the native ligand (KZ91367) was downloaded from the protein data bank 
database, and processed according to the procedure set out in the experimental. Two 
compounds (1 and 7), potent against both HeLa and HEK 295 cancer cell lines, were docked 
along with the reference drug (5-FU) into the binding site of Eg5, using the CDocker 
algorithm (Wu et al., 2003) embedded in Discovery Studio (DS).  
 
The computed binding energy (BE) data suggested good binding affinity of the compounds 
with Eg5. Both the synthesized molecules, 1 (BE= -180.25 kcal mol-1) and 7 (BE = -140.9 
kcal mol-1) were found to be stronger inhibitors of Eg5 than 5-FU, supporting a good 
correlation between the binding affinity and anti-cancer activity, as both compounds were 
found to be more potent than 5-FU experimentally. Compound 1 (Figure 2-3a) formed three 
hydrogen bonds; two concurrent with Glu116 (2.09Å) and Gly117 (2.51Å) through its 
protonated –NH2 (proton donor) group and one with Arg221 (2.37Å) via its –CN (proton 
acceptor) functionality.  Additionally, an electrostatic interaction (with Glu116) and 
hydrophobic forces (with Pro137 and Leu214) were also observed. Compound 7 (Figure 
2-3b), displayed predominantly hydrophobic interactions with Eg5 residues (Glu116, Pro137, 
Leu214, Tyr211 and Arg119), although a hydrogen bond with Glu116 (2.49Å), a non-
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conventional hydrogen bond with Glu118 (2.88Å) and an electrostatic force with Glu116 





Figure 2-3 Docked poses of 1 (a) and 7 (b) in the binding site of Eg5. Both ligands are shown 
in lemon sticks whereas the interacting amino acids of Eg5 are depicted in green lines. 
Hydrogen bonds (conventional) as green, non-conventional hydrogen bonds as grey, 
hydrophobic as magenta and electrostatic interactions are shown as red dotted lines.  
 
The reference drug, 5-FU (Figure 2-4) displayed only few non-conventional hydrogen bond 
interactions with Glu118 (3.04Å), Gly117 (2.81Å) and Ala133 (2.54Å), and a hydrophobic 
force with Pro137 of Eg5. The presence of weaker hydrogen bonds and absence of other non-
bonded forces (hydrophobic and electrostatic) probably account for the lower binding energy 
of 5-FU in comparison to the other two compounds (1 and 7). Overall, the docking results 
suggest that the pyrimidine ring and –NH2 are very significant components of the synthesized 
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compounds and play very important roles in locking their structures in the binding site of 
Eg5.    
 
 
Figure 2-4  Docked pose of 5-FU (in lemon sticks) in the binding site of Eg5. The interacting 
amino acids of Eg5 are depicted in green lines. Non-conventional hydrogen bonds and 
hydrophobic interactions are shown as grey and magenta dotted lines.  
 
Finally, both compounds (1 and 7) were subjected to the Lipinski rule of five to determine 
their potential of being an oral drug in humans (Ertl et al., 2000; Lipinski et al., 2012). This 
rule states that for any compound to become an orally active drug the following criteria needs 
to be satisfied;  molecular weight (MW) less than 500 daltons, logP (an octanol-water 
partition coefficient) value less than 5,  number of hydrogen bond donors (HBDs)  less than 5 
and number of hydrogen bond acceptors (HBAs)  less than 10. The “Filter by Lipinski and 
Veber rule” algorithm in DS was used for these predictions. The computed parameters: MW, 
283 (for 1) and 343 (for 7); AlogP, 1.2 (for 1) and 1.16 (for 7); HBDs, 5 (for both 1 and 7) 
and HBAs, 7 (for 1) and 9 (for 7) were in agreement with the Lipinski rules, and suggested 
their potential of being orally active drugs. Finally, the polar surface area (PSA), a parameter 
that is very useful to assess the cell membrane permeability, of both compounds was 
computed using the same algorithm.  Generally, a PSA value < 140 Å2 indicates efficient 
membrane permeation (Ertl et al., 2000). The computed PSA values for 1 (PSA= 126.9) and 
7 (PSA= 145.3) favored the drug likeness of the former over the latter.  
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2.3 Material and Methods 
General Experimental Procedures 
Reagents and chemicals used in this study were purchased from Sigma Aldrich via Capital 
Laboratories, South Africa, and were reagent grade. All organic solvents were redistilled and 
dried according to standard procedures.  NMR spectra were recorded using a Bruker 
AvanceIII 400 MHz spectrometer at room temperature with chemical shifts () recorded 
against the internal standard, tetramethylsilane (TMS).  1H, 13C and 2D NMR spectroscopy 
(HSQC and HMBC) were used for the structural elucidation of the synthesized compounds.  
IR spectra were recorded on a Perkin Elmer Spectrum 100 FTIR spectrometer with universal 
ATR sampling accessory. For GC-MS analyses, the samples were analysed on an Agilent 
GC-MSD apparatus equipped with a DB-5SIL MS (30m × 0.25mm) fused-silica capillary 
column.  Helium (at 2 mL min−1) was used as a carrier gas.  The MS was operated in the EI 
mode at 70 eV.  Optical rotation was recorded on a Perkin Elmer, Model 341 Polarimeter.  
Melting points were recorded on an Ernst Leitz Wetzlar micro hotstage melting point 
apparatus.  
 
General Procedure for the synthesis of aromatic substituted pyrano[2,3-d]pyrimidiones 
(1-7) 
Substituted aromatic benzaldehydes (ArCHO), malononitrile, barbituric acid (1.0 mmol each) 
and 10% DABCO were dissolved in 20 mL of aqueous ethanol and stirred for 1 hour. The 
progress of the reaction was monitored by TLC.  The products were then filtered, 
recrystallized in ethanol and dried under vacuum to produce 1-7 in good yields of between 
90-96%.  Optical rotation of the synthesized compounds indicated that all the compounds are 
racemic mixtures. 
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7-amino-5-phenyl-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione (1)  white 
powder, yield 92%; mp 205-208 ºC; IR (KBr) υmax (cm-1): 3184 (NH2), 2194 (CN), 1718 
(C=O); EIMS (m/z, rel. int.) 282 [M+] (38), 207 (62), 193 (25), 154 (58), 127 (100). Anal. 
calc. for CHN: C: 59.57, H: 3.57, N: 19.85, O: 0.17, Found: C: 59.17, H: 3.46, N: 19.20, O: 
0.17.  
7-amino-5-(3-hydroxyphenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione (2) 
white powder (90%); mp 230-232 ºC; IR (KBr) υmax (cm-1): 3424 (NH2), 3176 (NH), 2828 
(CH), 2205 (CN), 1676 (C=O), 1459 (C=C); EIMS (m/z, rel. int.): 298 [M+] (10), 281 (96), 
208 (50), 207 (100), 193 (43), 191 (71); Anal. calc. for CHN:  C: 56.38, H: 3.38, N: 18.78, O: 
21.46, Found: C: 56.12, H: 3.01, N: 17.76, O: 20.98.  
7-amino-5-(3,4-dihydroxyphenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione 
(3) Light yellow powder (96%); mp 190-192 ºC; IR (KBr) υmax (cm-1): 3424 (NH2), 3176 
(NH), 2828 (CH), 2205 (CN), 1676 (C=O), 1459(C=C); EIMS (m/z, rel. int.): 314 [M+] (38), 
301 (21), 271 (28), 223 (27), 216 (53), 207 (100), 131 (92); Anal. calc. for CHN: C: 53.51, H: 
3.21, N: 17.83, O: 25.46, Found: C: 53.31, H: 2.99, N: 17.64, O: 25.28.  
7-amino-5-(3-methoxyphenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione (4) 
White powder (90%); mp 285-288 ºC; IR (KBr) υmax (cm-1): 3392 (NH2), 3172 (NH), 3049 
(CH), 2193 (CN), 1676 (C=O), 1462 (C=C);  EIMS (m/z, rel. int.):  312 [M+] (34), 282 (25), 
207 (100), 189 (27), 176 (19), 125 (42);  Anal. calc. for CHN: C: 57.69, H: 3.87, N: 17.94, O: 
20.94, Found: C: 57.45, H: 3.67, N: 17.39, O: 19.96.   
7-amino-5-(4-methoxyphenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione (5)  
Yellow powder (95%); mp 287-289 ºC; IR (KBr) υmax (cm-1): 3186 (NH2), 3071 (NH), 2832 
(CH), 2194 (CN), 1714 (C=O), 1439 (C=C); EIMS (m/z, rel. int.):  312 [M+] (12), 294 (64), 
42 
281 (43), 207 (100), 191 (82);   Anal. calc. for CHN: C: 57.69, H: 3.87, N: 17.94, O: 20.49, 
Found C: 56.99, H: 3.12, N: 17.52, O: 20.27.  
 7-amino-5-(2,3-dimethoxyphenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione 
(6)  White powder (94%); mp > 300 ºC; IR (KBr) υmax (cm-1): 3420 (NH2), 3261 (NH), 3162 
(CH), 2190 (CN), 1716 (C=O), 1479 (C=C); EIMS (m/z, rel. int.):  342 [M+] (8), 327 (16), 
281(16), 207 (100); Anal. calc. for CHN: C: 56.14, H:14.12, N: 16.37, O: 23.37, Found: C: 
56.05, H: 13.88, N: 16.08, O: 23.15.  
7-amino-5-(2,5-dimethoxyphenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-diones 
(7) Light yellow powder (95%); mp > 300 ºC; IR (KBr) υmax (cm-1): 3284 (NH2), 3171 (CH), 
2198 (CN), 1706 (C=O), 1462 (C=C); EIMS (m/z, rel. int.) 342 [M+] (8),  327 (8),  281 (16),  
244 (100),  229 (72), 207 (52), 201 (71);  Anal. calc. for CHN: C: 56.14, H: 4.12, N: 16.37, 
O: 23.37 Found: C: 56.07, H: 3.98, N: 16.07, O: 23.27.  
 
Antimicrobial Susceptibility Testing 
Antibacterial Assay 
The antimicrobial activity of the synthesized compounds (1-7) were tested against the Gram 
positive Staphylococcus aureus  ATCC 25923 and methicillin resistant Staphylococcus 
aureus ATCC BAA-1683 (MRSA), and three Gram negative strains, Escherichia coli ATCC 
25922, Pseudomonas aeruginosa ATCC 27853 and Klebsiella pneumonia ATCC 31488.  
The standard antibiotics Ciprofloxacin and Ampicillin were used as controls for comparison.  
Mueller Hilton agar (Biolab, South Africa) was prepared (38 g in 1 L of water), poured into 
sterile pre-labelled petri dishes and allowed to set and dry at room temperature.  Bacterial 
cultures were standardized using a 0.5 McFarland standard turbidity and then swabbed onto 
agar plates.  Paper discs were loaded with sample (20 µL) of the synthesised compounds and 
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placed onto the prepared agar plates, which were inverted and incubated at 35-37°C for 24 
hours.  The diameter of the zone of inhibition was measured in mm.   Compounds showing an 
inhibition zone of > 9 mm were selected to determine their MBC values using the broth 
dilution assay with Ampicillin and Ciprofloxacin as the controls following the method in 
Andrews (2001). Compounds 3, 5 and 6 were chosen for the broth dilution method to 
determine their MBCs. 
 
The compounds were dissolved in DMSO (10 mg mL-1), serially diluted with Mueller-Hinton 
broth (Oxoid, England), inoculated with the respective bacterial cultures and incubated at 
37oC for 18 hours. This was performed in duplicate.  Thereafter, 10 µL from each 
concentration was placed on Mueller-Hinton plates and incubated at 37oC for 18 hours to 
determine the MBC. The MBC was the lowest concentration which showed no bacterial 
growth in the area in which the sample was placed.   
 
Cytotoxicity tests by MTT assays 
Human cervical cancer cells (HeLa) and human colon adenocarcinoma cells (Caco-2) were 
purchased from Highveld Biological (Pty) Ltd. (Lyndhurst, RSA). HEK293 cells (human 
embryonic kidney) were obtained from the Medical School, University of Witwatersrand 
(Gauteng, South Africa). All cells were grown to semi-confluency in 25 cm2 tissue culture 
flasks in EMEM (Eagle's Minimum Essential Medium, Lonza BioWhittaker, Verviers, 
Belgium) supplemented with 10% fetal bovine serum and antibiotics (100 U mL-1 penicillin, 
100 µg mL-1 streptomycin).  For the MTT assay, cells were seeded at a density of 1.8 x103 
cells per well in a 96 well plate containing 100 µL of medium. The cells were then incubated 
for 24 h at 37 ºC in 5% CO2, after which the medium was removed and 100 µL fresh medium 
was added. Thereafter, compounds 1-7 at concentrations of 10, 25, 50 and 100 µg mL-1 was 
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added in triplicate to the cells and incubated for 48 h at 37 ºC. 5FU was used as a standard 
positive control. 
 
The MTT assay was adapted from Mossman (1983).  It measures the metabolic activity of 
cells by the reduction of MTT to formazan using the succinate-tetrazolium reductase system. 
After 48 h of incubation, the spent medium was replaced with 100 µL fresh medium and 100 
µL of MTT (5 mg mL-1 in PBS), and cells were incubated for 4 h at 37 ºC. Thereafter, the 
medium and MTT were removed, and 200 µL of DMSO added to each well to dissolve the 
formazan salt. The absorbance of the resulting purple solution was read in a Mindray 96A 
microplate reader (Vacutec, Hamburg, Germany) at 570 nm (detection l) and 630 nm 
(reference l for nonspecific signals) wavelengths. Cell viability (%) was directly correlated to 
absorbance and calculated in comparison to the untreated control as follows: 
[(OD570Treated - OD630Treated) / (OD570Control - OD630Control) x 100)] 
Tests were conducted in triplicate and calculation of the concentration at which 50% cell 
death (IC50) was achieved by plotting the data on graphs using Microsoft Excel 2010™. 
 
Docking Methodology 
Three dimensional co-ordinates of human kinesin Eg5 were obtained from its X-ray structure 
(pdb id: 2x7c) co-crystallized with its native ligand (KZ91367) in the protein data bank 
database (www.rcsb.org). The duplicate chain and water molecules of the protein were 
removed, and protonation of different amino acids determined based on their pKa values 
using “Prepare Protein” algorithm in DS.  Different isomers of the RCs and 5-FU were 
generated using the “Prepare ligands” module, and minimized. The isomer with the lowest 
CHARMm energy was selected for docking. A binding sphere covering the binding site 
residues of Eg5 was generated using the “Define and edit binding site” module.  Docking of 
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all compounds was performed using the CDocker Algorithm (Wu et al., 2003), a CHARMm 
force field based program. The conformational space of each ligand, during docking, was 
explored using molecular dynamics method and refined by grid-based simulated annealing 
method. The top 10 poses were arranged according to the -CDocker energy, and the one with 
lowest energy was used for binding energy calculations.  
 
2.4 Conclusion 
In conclusion we have reported and described an eco-compatible synthesis of pyrano[2,3-
d]pyrimidinone derivatives using a green and efficient catalyst, DABCO, which has the 
advantage of operational simplicity, mild reaction conditions and high yields of the final product.  
A structural elucidation including 1H and 13C NMR assignments are also made and will aid in 
identifying similar compounds synthesized.  Compounds 3, 5 and 6 showed promising 
antibacterial activity, with 6 showing excellent potential as a lead antibiotic.  Both compounds 3 
and 6 have the potential to be developed into an antibiotic against MRSA.  Compounds 1, 2, 5 
and 7 showed excellent activity against HeLa cells with 2, 5 and 7 being approximately ten times 
more active than the standard 5FU.  These compounds are therefore good lead compounds for 
anticancer agents. Additionally, the docking simulations suggested good binding affinity of the 
compounds with Eg5 and indicated their anti-cancer action, at least partially, through its 
inhibition. The predicted Lipinski descriptors also indicated the potential of these compounds to 
be an orally active drug. 
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Chapter 3. Synthesis of chloro, fluoro and nitro derivatives of 7-amino-5-
aryl-6-cyano-5H-pyrano pyrimidin-2,4-diones using organic catalysts 
and their antimicrobial and anticancer activities  
 
* The compounds referred to in this chapter are referred to in the abstract, conclusion and appendices or 
elsewhere in the thesis with a B preceding the number of the compound, with the exception of compound 1, 




A range of substituted 7-amino-5-aryl-6-cyano-5H-pyrano pyrimidin-2,4-dione derivatives 
were synthesized in a one-pot reaction by reacting malononitrile and barbituric acid with 
aromatic aldehydes in the presence of 1,4-diazabicyclo[2,2,2]octane (DABCO) in aqueous 
medium.  This is the first report of these compounds being synthesized with DABCO as a 
catalyst, which produced the compounds in yields in excess of 90%.  The 2,4-difluoro (11) 
derivative was novel.  The structures of the synthesized compounds were elucidated by 
means of 1H, 13C NMR and 2D NMR spectroscopy.  Compound 2 (2-Cl derivative) had MBC 
values of < 200 µM against both S. aureus and MRSA and the 2-nitro derivative 5 had an 
MBC of 191 µM against the Gram –ve E. coli.  The synthesized compounds were also tested 
for their anticancer activity against a HeLa cell line, where all the compounds showed better 
activity (IC50 values ranging from 129 to 340 µM) than 5-fluorouracil, a commonly known 
anticancer drug. 
. 
Keywords: Pyrano pyrimidinone, malononitrile, barbituric acid, HeLa, anticancer. 
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3.1 Introduction 
Pyrimidines and its analogues are an important class of heterocyclic compounds and their 
structural skeleton is a key constituent of nucleic acids, alkaloids and numerous other 
pharmacophores with a variety of potent biological activities (Ajani et al., 2015).  
Pyrano[2,3-d]pyrimidines consists of a pyran ring fused together with pyrimidine. As such, 
their basic framework consists of both nitrogen and oxygen in their carbocyclic structure.  
This pyrimidine annulated derivative is known to possess good pharmacological activity such 
as antioxidant, antidiabetic (Yousefi et al., 2015), antimicrobial (Paliwal et al., 2013; 
Mohamed et al., 2007), anti-inflammatory, analgesic (Kadry, 2014), moderate anticancer 
(Mohamed et al., 2007), antimycobacterial (Read et al., 2010) and antimalarial activity (Joshi 
et al., 2005). 
 
Pyrimidines are generally synthesized by a Biginelli multicomponent reaction (MCR), a 
method considered green since they are fast, solvent free, produces good yields and avoids 
exposing the environment to environmentally harmful intermediates (Gore and Rajput, 2013). 
Pyrano[2,3-d]pyrimidines are commonly formed from barbituric acid, malonitrile and 
aldehdyes with a catalyst such as the organic catalyst 1,4-diazabicyclo[2,2,2]octane 
(DABCO) (Jain et al., 2014), a mesoporous solid acid catalyst (SBA-15-Pr-SO3H) (Ziarini et 
al., 2013), a ZnFe2O4 nanocatalyst (Khazaei et al., 2015), a nano-sawdust-OSO3H catalyst 
(Sadeghi et al., 2015), a Mn doped ZrO2 catalyst (Maddila et al., 2015) or triethylammonium 
acetate (a green catalyst) (Paliwal et al., 2013).  The same compounds were made using an 
arylidenemalonitrile with barbituric acid under microwave irradiation without a catalyst (Gao 
et al., 2004) or using ionic liquid catalysts such as N-butyl-N-methyl imidazole 
tetrafluoroborate [BMIm]BF4, N-ethyl-N-methyl imidazole tetrafluoroborate [EMIm]BF4 or 
N-butyl pyridinium tetrafluoroborate [BPy]BF4 (Yu and Wang, 2005).  The resultant 
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pyrimidine diones usually have a substituted phenyl group at position 5 and reactive nitrile 
and amino groups at positions 6 and 7 on the pyrano[2,3-d]pyrimidine skeleton.   
 
By reacting ethyl 2-cyanoacetate with barbituric acid and substituted benzaldehydes in the 
presence of DABCO, an ethyl ester group was placed at C-6 instead of the nitrile group (Bhat 
et al., 2014). Pyrano[2,3-d]pyrimidines with phenyl groups at both positions 5 and 7 were 
synthesized by the reaction of chalcones with barbituric acid in the presence of acetic acid 
and P2O5 as a catalyst (Rahman et al., 2013).   
 
Other pyrimidines with substituted phenyl groups were synthesized in a one-pot reaction with 
1-nitroguanidine, malonitrile and substituted benzaldehydes under basic conditions in a one 
pot reaction with short reaction times, mild reaction conditions and excellent yields (Xia et 
al., 2012) or with guanidine nitrate, ethylcyanoacetate and aldehydes using piperidine as a 
catalyst (Bhatewara et al., 2012).  Spiropyrimidinones were synthesized using urea instead of 
malonitrile together with barbituric acid and benzaldehydes in the presence of a nanoporous 
solid acid catalyst (SBA-Pr-SO3H) (Ziarini et al., 2015).  A totally different synthesis to 
pyrano[2,3-d]pyrimidines was achieved using a one-pot three component reaction of 2-
amino-7-methyl-5-oxo-4-phenyl-4,5-dihydropyrano[4,3-b]pyran-3-carbonitriles, N,N-
dimethylacetaldehyde dimethyl acetal and aromatic amines in the presence of 1-butyl-3-
methylimidazole hydrogen sulphate (an ionic liquid) as a catalyst (Suresh et al., 2015).  
Another synthesis reports the use of N,N-dimethyl-5-formylbarbituric acid with maleimide 
and phenyl isocyanate under microwave irradiation to afford pyrano[2,3-d]pyrimidines in 
good yields (Devi et al., 2004). 
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We herein report the synthesis of a small library of chloro, nitro and fluoro 7-amino-5-aryl-6-
cyano-5H-pyrano [2,3-d]pyrimidin-(1H,3H)-2,4-diones using DABCO as a catalyst together 
with their antibacterial and anticancer activity. 
 
3.2 Results and Discussion 
Chemistry 
The title compounds were synthesized in a one pot reaction from substituted chloro, fluoro 
and nitro aromatic benzaldehydes (ArCHO), malononitrile, barbituric acid and DABCO in  
aqueous ethanol (Figure 3-1) to produce 7-amino-5-aryl-6-cyano-5H-pyrano[2,3-
d]pyrimidin-(1H,3H)-2,4-diones (1-11) in yields of between 90-96% (Table 3-1).  The 
structures of the products were confirmed from their 1H and 13C NMR spectra and the 
resonances assigned with the aid of 2D HSQC and HMBC spectra. 
 
With the exception of the novel, 2,4-difluoro derivative 11, all the compounds were 
synthesised previously in comparable yields using a variety of methods  or catalysts (Table 
3-1) including microwave synthesis without the use of a catalyst (Gao et al., 2004), with the 
ionic liquids 1-n-butyl-3-methylimidazolium tetrafluoroborate and 1-butylpyridinium 
tetrafluoroborate (Yu and Wang, 2005), a Zn [(L) proline] catalyst (Heravi et al., 2010), with 
glycerol without the use of a catalyst (Safaei et al., 2012), nanocatalysts Fe3O4 (Kidwai et al., 
2012) and SBA-15-Pr-SO3H (a mesoporous solid acid catalyst) (Ziarini et al., 2013) and ethyl 
cyanoacetate (Sharanin and Klokol, 1984).  DABCO has been used previously for the 
synthesis of furan-2-yl, pyrrol-2-yl and thiophen-2-yl derivatives of pyrano pyrimidin-2,4-
diones in a one pot reaction, but there are no reports of this catalyst being used in the 




Figure 3-1  DABCO catalyzed reaction of pyrano pyrimidine derivatives (1-11)   
 
This reaction occurs via proton removal from the methylene group of malonitrile, which 
subsequently forms an arylidene derivative via a Knoevenagel condensation.  This arylidene 
derivative then undergoes a Michael reaction with barbituric acid and subsequent cyclization 
results in the pyrano [2,3-d] pyrimidinones.  Plausible mechanisms are provided in Bhat et al. 
(2004) and Jain et al. (2014), however these mechanisms are either not quite clear or misses 
out some steps.  A more comprehensive mechanism is presented in Figure 3-2. 
 
Four basic organic catalysts and K2CO3 were investigated for this one-pot reaction under 
reflux conditions at 80 ºC with equimolar quantities of benzaldehyde, malonitrile and 
barbituric acid in a mixture of 1:1 ethanol and water to identify the catalyst among them that 
produced the greatest yield in the shortest amount of time.  The organic catalysts investigated 
were L-proline, dibutylamine (DBA), triethylamine (Et3N) and 1,4-diazabicyclo [2.2.2] 
octane (DABCO).  Of these, DBA, Et3N and DABCO resulted in yields of over 70% in 
approximately one hour (Table 3-2).  DABCO performed the best, producing yields of 94% 
in 38 minutes.  DBA and Et3N also produced acceptable yields in approximately one hour, 




Figure 3-2  A plausible mechanism for the one pot reaction of malonitrile, barbituric acid and 
benzaldehydes in the presence of DABCO. 
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Table 3-1  Yields and melting points of aromatic pyrano [2,3-d] pyrimidines catalyzed by 
DABCOa 
Entry R Yield  mp (oC) Reference Yield Catalyst/method 
1 H  90 205-208 Gao et al. (2004)  
Yu and Wang (2005) 
Heravi et al. (2010) 







Zn [(L) proline] 
SBA-Pr-SO3Hf 
2 2-Cl  93 212-215   Gao et al. (2004) 
Yu and Wang (2005) 







3 3-Cl 91 223-225 Safaei et al. (2012) 





4 4-Cl  93 235-237  Gao et al. (2004) 
Yu and Wang (2005) 
Heravi et al. (2010) 
Ziarani et al. (2013) 
Safaei et al. (2012) 













5 2-NO2  96 258-259   Safaei et al. (2012) 92 Glycerold 
6 3-NO2  92 256-258     Heravi et al. (2010) 
Ziarani et al. (2013) 




Zn [(L) proline] 
SBA-Pr-SO3Hf 
Glycerold 
7 4-NO2 90 225-228 Gao et al. (2004) 
Heravi et al. (2010) 
Ziarani et al. (2013) 
Safaei et al. (2012) 











8 2-F 92 226-229 Commercially 
availableb 
  




10 4-F 90 228-230 Gao et al. (2004) 





11 2,4-diF 93 250-252 novel   
 
aReaction conditions: barbituric acid (1.0 mmol), substituted benzaldehydes (1.0 mmol) and malononitrile (1.1 
mmol), EtOH:water (1:1 v/v, 10 mL), room temp.; bAkos Consulting and Solutions; Sigma Aldrich; cThe 7-
indolyl group replaces the substituted aromatic group; dno catalyst; eionic liquids – 1-n-butyl-3-




Table 3-2  Yields and reaction times for the one-pot reaction of pyranopyrimidinones with 
different catalystsa 
Catalyst Time (min) 
Yield 
% 
No catalyst 1080 (18h) 5 
L-Proline 180 (3h) 45 
K2CO3 110 57 
DBA 54 74 
Et3N 70 81 
DABCO 38 94 
a Reagents and reaction conditions: barbituric acid (1.0 mmol), benzaldehyde (1.0 mmol) and malononitrile (1.1 
mmol), EtOH:water (1:1 v/v, 10 mL), room temp. 
 
The 1H and 13C NMR spectra were similar for all compounds and the only difference in the 
spectra were brought about by differences in the aryl moiety of the molecule substituted at C-
5.  Using compound 1 (the pyrimidine with the unsubstituted aryl ring) as an example, a 
characteristic H-5 resonance was seen at δ 4.26.  This was an indication that the 
pyranopyrimidines had formed.  The only other protons on the core pyrimidine skeleton, 
were the 1º and 2º amino and amide protons.  The NH2-11 resonance occurred at δ 7.14 as a 
two proton singlet together with the aromatic protons at δ 7.18-7.22 (H-2',4',6'), and δ 7.29-
7.32 (H-3',5'). NH2-11 showed HMBC correlations with both C-6 and C-7, supporting this 
assignment.  The NH-1 and NH-3 proton resonances occurred at δ 11.08 (sharp singlet) and δ 
12.07 (broadened singlet), however, these resonances could not be assigned unequivocally 
and are interchangeable. 
 
The core structure of the pyrano[2,3-d]pyrimidines synthesized in this work have very 
characteristic carbon resonances. The nitrile carbon C-10, pyrimidine carbon C-9, pyran 
carbon C-6 to which the nitrile group is attached and the methine carbon C-5 of the pyran 
ring to which the aromatic group is attached all appear very distinctly at δ 119.1 (C-10), 88.5 
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(C-9), 58.7 (C-6) and 35.6 (C-5).  There are five downfield carbon resonances.  The most 
shielded resonance at δ 144.2 was assigned to the aromatic carbon C-1' due to a HMBC 
correlation with H-3',5' and C-7 was assigned to δ 157.7 due to a HMBC correlation with 
NH2-11.   The other three carbon resonances in this region at δ 149.4 (C-2), 152.4 (C-8) and 
162.4 (C-4) were characteristic of the pyrimidinone carbon resonances.  The HMBC 
correlations of H-5 were instrumental in assigning the carbon resonances on the core 
structure (Figure 3-3).  H-5 showed HMBC correlations to C-8, C-9 and C-4 of the 
pyrimidine ring, C-6 and C-7 of the pyran ring, C-1', C-2' and C-6' of the phenyl ring and the 
cyano carbon C-10.   
 
 
Figure 3-3  Selected HMBC correlations for compound 1 
 
Antimicrobial activity 
The synthesized compounds were tested for their antimicrobial activity against two Gram +ve 
and three Gram –ve strains of bacteria.  The compounds were initially screened for their 
antimicrobial potential using the disk diffusion assay, where compounds showing a mean 
inhibition zone of greater than 9 mm were selected to determine their minimum bactericidal 
concentrations (MBCs).  In general, the compounds were more active against the Gram +ve 
Staphylococcus aureus and MRSA than the Gram –ve strains (Table 3-3).  Compound 2, the 
2-chloro derivative was active at < 200 µM for both the Gram +ve strains.  Several of the 
compounds were also active at < 200 µM against MRSA, showing better activity than 
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ampicillin.  Only compound 5, the 2-nitro derivative showed activity < 200 µM against E. 
coli.  None of the other compounds showed any appreciable activity to the Gram –ve strains. 
 
Table 3-3  Antibacterial activity of the synthesized compounds 
Bacterial strains Minimum Bactericidal Concentration  (µM) 
Compounds 2 3 4 5 8 11 AMP CIP 
Gram +ve         
S. aureus 197 394 394 382 208 196 56 1.84 
MRSA 197 197 394 191 1665 393 894 7.36 
Gram -ve         
E. coli 1579 1579 789 191 1665 786 447 1.84 
P. aeruginosa 1579 1579 789 1528 1665 1571 1788 1.84 
K. pneumoniae 394 789 1579 382 1665 1571 447 3.68 
Data is reported as the average of duplicate readings 
 
MTT cytotoxicity assay 
The in vitro cytotoxicity levels of compounds 1-11 in the HeLa cells are summarized in 
Table 3-4 below.  Most of the compounds tested showed a typical dose dependent 
cytotoxicity profile. Based on the IC50 values it can be deduced that all compounds are most 
active at concentrations greater 100 µg mL-1. The activities of all compounds were better than 
5-fluorouracil (5FU), a commonly used anticancer drug, with IC50 values ranging from 129 to 
340 µM.  5FU had an IC50 in the same assay at 480 µM.  The activities of the compounds 
could be due to the pyranopyrimidinone core structure, with aryl groups at C-5 to which 
electron withdrawing groups were attached.  Compounds 3, 4, 7 and 8 were active at a much 
lower dose, which augurs well for their future use as possible anti-cancer agents. Further 
studies and testing of high activity compounds are hence warranted. 
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Table 3-4  Viabilities (%) of the HeLa cell lines at different concentrations of compounds 1-11  
Cpd 10 µg mL-1 25 µg mL-1 50 µg mL-1 100 µg mL-1 IC50 µg mL-1 IC50 µM 
1 95.58±0.02c 85.82±0.0005b,c 70.10±0.01b 41.35±0.02a 84.92 301 
2 96.72±0.01d 83.06±0.01c 65.40±0.02b 40.48±0.01a 81.34 257 
3 79.11±0.01d 65.64±0.001c 53.20±0.02b 43.33±0.04a 74.02 234 
4 72.08±0.02d 52.13±0.02c 37.99±0.02b 27.84±0.02a 40.67 129 
5 98.22±0.03d 82.46±0.01c 69.79±0.02b 46.68±0.02a 90.86 278 
6 95.81±0.02d 78.36±0.01c 69.31±0.02b 57.15±0.02a 111.27 340 
7 86.65±0.02d 73.82±0.02c 62.80±0.01b 40.64±0.02a 78.81 241 
8 81.04±0.02d 68.92±0.01c 50.87±0.03a 42.54±0.03a 72.54 242 
9 87.88±0.02c 83.25±0.01c 69.91±0.01b 50.91±0.03a 101.11 337 
10 88.55±0.02d 69.79±0.01c 57.86±0.01b 41.19±0.01a 96.51 322 
11 84.79±0.01c 77.37±0.02c 63.67±0.02b 52.41±0.02a 101.2 318 
12 90.28±0.01d 85.15±0.01c 71.56±0.01a 71.56±0.02a 108.75 339 
5FU 78.40±0.03d 58.89±0.03b 50.47±0.02b 38.00±0.02a 62.41 480 
Data are presented as the mean ± SD value of triplicate determinations. a-d Different superscript letters for a 
given value within a column are significantly different from each other (Tukey’s-HSD multiple range post hoc 
test, p < 0.05). 
 
Molecular docking studies 
In order to support the experimental anti-cancer activity of the synthesized compounds and to 
predict their mechanism of action, two representative compounds (RCs) 4 (4-Cl) and 8 (2F) 
were docked and observed to be potent under in vitro conditions, into the binding site of 
human kinesin protein, Eg5. The CDocker docking method embedded in the Discovery 
Studio (DS) was used for all docking simulations.  The docking results obtained suggested 
both compounds to be strong inhibitors of Eg5 based on the computed binding energy (BE) 
data. The most active compound 4 with BE of value -184.4 kcal mol-1 exhibited a stronger 
interaction than its structural analogue 8 (BE = -150.1 kcal mol-1). Both the RCs exhibited 
stronger binding affinity for Eg5 relative to the standard drug, 5FU (BE = -116.7 kcal mol-1).  
To understand the host-guest relationship between ligand and receptor, the docked complexes 
of both RCs were further visualized using DS visualizer, and are diagrammatically 
represented in Figure 3-4 and Figure 3-5.  Compound 4 (Figure 3-4) exhibited two 
concurrent hydrogen bond interactions through its protonated amine functionality (NH2) with 
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Glu116 (1.81 Å) and Gly117 (1.98 Å) amino acid residues of Eg5. Additionally, an 
electrostatic interaction between 4 and Glu116 including several hydrophobic forces (with 
Pro137, Trp127, Arg119, Tyr211 and Ala133) were also observed. Similarly, 8 (Figure 3-5) 
interacted with Eg5 through two hydrogen bonds; one conventional with Arg221 (1.17Å) 
through its nitrile group and another non-conventional with Arg119 (2.80 Å) through the 
nitrogen atom of the pyrimidine ring. In addition, two electrostatic interactions (with Glu116 




Figure 3-4  Docked pose of 4 in the binding site of Eg5. Hydrophobic and electrostatic 
interactions are shown as magenta and red dotted lines respectively.  Conventional hydrogen 




Figure 3-5  Docked pose 8 in the binding site of Eg5. Hydrophobic and electrostatic 
interactions are shown as magenta and red dotted lines respectively.  Conventional hydrogen 
bonds are shown as green and non-conventional hydrogen bonds are shown as grey. 
 
3.3 Materials and Methods 
General Experimental Procedures 
Reagents and chemicals used in this study were purchased from Sigma Aldrich via Capital 
Laboratories, South Africa, and were reagent grade.  All organic solvents were redistilled and 
dried according to standard procedures.  NMR spectra were recorded using a Bruker 
AvanceIII 400 MHz spectrometer at room temperature with chemical shifts () recorded 
against the internal standard, tetramethylsilane (TMS).  2D NMR spectroscopy (HSQC, and 
HMBC) were used for the structural elucidation of the synthesized compounds.  IR spectra 
were recorded on a Perkin Elmer Spectrum 100 FTIR spectrometer with universal ATR 
sampling accessory.  For GC-MS analyses, the samples were analyzed on an Agilent GC-
MSD apparatus equipped with a DB-5SIL MS (30 m × 0.25 mm) fused-silica capillary 
column.  Helium (at 2 mL min−1) was used as a carrier gas. The MS was operated in the EI 
mode at 70 eV.  Optical rotation was recorded using a Perkin Elmer, Model 341 Polarimeter. 
Melting points were recorded on an ErnstLeitzWetzlar micro hot stage melting point 
apparatus and are uncorrected.  
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General procedure for the synthesis of aromatic substituted pyrano [2,3-d] 
pyrimidinones (1-11) 
Substituted aromatic benzaldehydes (1.0 mmol each), malononitrile (396 mg, 1.0 mmol), 
barbituric acid (640 mg, 1.0 mmol each) and 10 mol % DABCO (30.45 mg, 0.271 mmol) 
were added to 20 mL of aqueous ethanol (Figure 3-1) and the reaction mixture stirred for 1 
hour at room temperature.  The progress of the reaction was monitored by TLC. The products 
were filtered, recrystallized in ethanol and dried under vacuum.   
 
(1)  7-amino-5-phenyl-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione, white 
powder (92% yield); mp 205-208 ºC; UV λmax (DMSO) nm (log ϵ) 312 (2.66); IR (KBr) νmax: 
3184 (NH2), 2194 (CN), 1718 (C=O), 1674 (C=O) cm-1;  1H NMR (400 MHz, DMSO) δH 
12.07 (brs, NH) 11.08 (s, NH), 7.29-7.32 (2H, m, H-3',5'), 7.18-7.22 (3H, m, H-2',4′,6'), 7.14 
(s, NH2-11), 4.26 (1H, s, H-5); 13C NMR (100 MHz, DMSO) δC  162.4 (C-4), 157.7 (C-7), 
152.4 (C-8), 149.4 (C-2), 144.2 (C-1'), 129.4 (2CH, C-2',6'), 128.2 (2CH, C-3',5'), 127.4 (CH, 
C-4'), 119.1 (C-10), 88.5 (C-9), 58.7 (C-6), 35.6 (CH, C-5);  EIMS (m/z, rel. int.) 282 [M+] 
(38), 207 (62), 193 (25), 154 (58), 127 (100); Anal. calc. for CHN: C: 59.57, H: 3.57, N: 
19.85, Found: C: 59.17, H: 3.46, N: 19.20.  
(2) 7-amino-5-(2-chlorophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione, 
white powder, (93% yield); mp 212-215 ºC; UV λmax (DMSO) nm (log ϵ) 259 (2.74); IR 
(KBr) νmax: 3013 (NH), 2192 (CN), 1714 (C=O), 1673 (C=O) cm-1; 1H NMR (400 MHz, 
DMSO) 12.07 (brs, NH) 11.04 (s, NH), 7.36 (1H, d, J = 8.0 Hz, H-6'), 7.21-7.27 (3H, m, H-
3',4',5'), 7.12 (s, NH2-11), 4.72 (1H, s, H-5); 13C NMR (100 MHz, DMSO) δC 162.2 (C-4), 
157.8 (C-7), 152.7 (C-8), 149.5 (C-2), 140.7 (C-1'), 132.2 (C-2'), (130.4, 129.5, 128.4, 127.4 
(4CH, C-3',4',5',6')), 118.7 (C-10), 87.5 (C-9), 56.0 (C-6), 30.6 (CH, C-5); EIMS (m/z, rel. 
int.) 316 (M+) (14), 281 (31), 207 (100), 273 (14), 189 (15); Anal. calc. for CHN: C: 53.09, 
H: 2.86, N: 17.69, Found: C: 53.00, H: 2.79, N: 17.60.   
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(3)  7-amino-5-(3-chlorophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione, 
white powder, (95% yield); mp 223-225 ºC; UV λmax (DMSO) nm (log ϵ) 259 (2.69); IR 
(KBr) νmax: 3417 (NH), 3317 (NH), 2192 (CN), 1706 (C=O), 1660 (C=O)cm-1; 1H NMR (400 
MHz, DMSO) δH 12.07 (brs, NH), 11.07 (s, NH), 7.32 (1H, t, J = 8.4 Hz, H-5'), 7.26-7.28 
(2H, m, H-4',6'), 7.19 (1H, s, H-2'), 7.16 (s, NH2-11), 4.26 (1H, s, H-5); 13C NMR (100 MHz, 
DMSO) δC 162.4 (C-4), 157.6 (C-7), 152.4 (C-8), 149.5 (C-2), 146.6 (C-1'), 132.8 (C-3'), 
130.1 (C-4'), 127.2 (CH, C-6'), 126.7 (CH, C-2'), 126.1 (CH, C-5'), 118.9 (C-10),  87.7 (C-9),  
58.1 (C-6), 35.4 (CH, C-5);  EIMS (m/z, rel. int.) 316 (M+) (6), 281 (11), 207 (100), 188 (22), 
153 (33); Anal. calc for CHN: C: 53.09, H: 2.86, N: 17.69, Found: C: 53.10, H: 2.59, N: 
17.70.  
(4) 7-amino-5-(4-chlorophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione, 
white powder, (94% yield); mp 235-237 ºC; UV λmax (DMSO) nm (log ϵ) 258 (2.68);  IR 
(KBr) υmax: 3383 (NH2), 3186 (NH), 2197 (CN), 1717 (C=O), 1672 (C=O) cm-1;  1H NMR 
(400 MHz, DMSO) δH 12.06 (brs, NH), 11.05 (s, NH), 7.33 (2H, d  J = 8.4 Hz, H-3',5'), 7.23 
(2H, d,  J = 8.4 Hz, H-2',6'), 7.13 (s, NH2-11), 4.24 (1H, s, H-5); 13C NMR (100 MHz, 
DMSO) δC 162.4 (C-4), 157.6 (C-7), 152.3 (C-8), 149.5 (C-2), 143.1 (C-1'), 131.2 (C-4'), 
129.3 (2CH, C-2',6'), 128.2 (2CH, C-3',5'), 119.0 (C-10),  88.0 (C-9), 58.3 (C-6), 35.1 (CH, 
C-5);   EIMS (m/z, rel. int.) 316 (M+) (15), 281 (33), 207 (100), 188 (25), 153 (23); Anal. 
calc. for CHN: C: 53.09, H: 2.66, N: 17.65, Found: C: 53.09, H: 2.86, N: 17.69.   
(5) 7-amino-5-(2-nitrophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione, off 
white powder, (96% yield); mp 258-259 ºC; UV λmax (DMSO) nm (log ϵ) 260 (2.71);   IR 
(KBr) υmax -1:  3365 (NH2),   2198 (CN),  1697 (C=O), 1618 (C=O) cm-1; 1H NMR (400 MHz, 
DMSO) δH 12.14 (brs, NH) 11.06 (s, NH), 7.82 (1H, d, J = 8.3 Hz, H-6'), 7.65 (1H, dd, J = 
8.1, 7.6 Hz, H-4'), 7.49 (1H, d, J = 7.6 Hz, H-3'),  7.45 (1H, dd, J = 8.3, 8.1 Hz, H-5'),  7.27 
(s, NH2-11), 5.04 (1H, s, H-5); 13C NMR (100 MHz, DMSO) δC 162.4 (C-4), 158.4 (C-7), 
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152.3 (C-8), 149.4 (C-2), 149.2 (C-2'), 138.1 (C-1'), 133.3 (CH, C-6'), 130.7 (CH, C-4'), 
128.0 (CH, C-3'), 123.7 (CH, C-5'), 118.6 (C-10),  87.9 (C-9), 56.7 (C-6), 30.3 (CH, C-5); 
EIMS (m/z, rel. int.) 327 (M+) (14), 298 (32), 207 (100); Anal. calc. for CHN: C: 51.38, H: 
2.77, N: 21.40,  Found: C: 51.04, H: 2.47, N: 21.36. 
(6) 7-amino-5-(3-nitrophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione,  off 
white powder, (90% yield); mp 256-258 ºC; UV λmax (DMSO) nm (log ϵ) 262 (2.77);  IR 
(KBr) υmax: 3414 (NH2), 3202 (NH), 2192 (CN), 1707 (C=O), 1687 (C=O) cm-1; 1H NMR 
(400 MHz, DMSO) δH 12.15 (brs, NH), 11.09 (s, NH), 8.08 (1H, d, J = 8.1 Hz, H-6'), 8.06 
(1H, brs, H-2'), 7.74 (1H, d, J = 7.7, H-4'), 7.60 (1H, dd, J = 8.1, 7.7 Hz, H-5'),  7.26 (s, NH2-
11), 4.47 (1H, s, H-5); 13C NMR (100 MHz, DMSO) δC 162.5 (C-4), 157.8 (C-7), 152.5 (C-
8), 149.5 (C-2), 147.7 (C-1'), 146.4 (C-3'), 134.7 (C-2'), 129.8 (CH, C-6'), 122.0 (CH, C-4'), 
121.9 (CH, C-5'), 118.8 (C-10),  87.4 (C-9), 57.6 (C-6), 35.4 (CH, C-5); EIMS (m/z, rel. int.):  
327 (M+) (15), 281 (40), 207 (100); Anal. calc. for CHN: C: 51.38, H: 2.77, N: 21.40, Found: 
C: 51.01, H: 2.46, N: 21.24.  
(7) 7-amino-5-(4-nitrophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione, white 
powder, (93% yield); mp 225-228 ºC; UV λmax (DMSO) nm (log ϵ) 260 (2.84); IR (KBr) υmax 
(cm-1): 3186 (NH), 2196 (CN), 1720 (C=O), 1671 (C=O) cm-1; 1H NMR (400 MHz, DMSO) 
δH 12.15 (brs, NH), 11.10 (s, NH), 8.15 (2H, d, J = 8.7 Hz, H-3',5'), 7.52 (2H, d, J = 8.7 Hz, 
H-2',6'), 7.25 (s, NH2-11), 4.41 (1H, s, H-5); 13C NMR (100 MHz, DMSO) δC 162.4 (C-4), 
157.7 (C-7), 152.6 (C-8), 151.7 (C-4'), 149.5 (C-2), 146.4 (C-1'), 128.8 (2CH, C-2',6'), 123.5 
(2CH, C-3',5'), 118.8 (C-10),  87.4 (C-9),  57.4 (C-6), 35.6 (CH, C-5); EIMS (m/z, rel. int.): 
327 (M+) (27), 207 (100); Anal. calc. for CHN: C: 51.38, H: 2.77, N: 21.40, Found: C: 50.93, 
H: 2.37, N: 21.16.   
(8) 7-amino-5-(2-fluorophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione, 
white powder; (90% yield);  mp 226-229 ºC; UV λmax (DMSO) nm (log ϵ) 260 (2.93);  IR 
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(KBr) υmax cm-1:  3421 (NH), 3303 (NH), 2203 (CN),  1716 (C=O), 1692 (C=O) cm-1; 1H 
NMR (400 MHz, DMSO) δH  12.11 (brs, NH), 11.07 (s, NH), 7.23-7.28 (2H, m, H- 4',6'), 
7.14 (2H, s, NH2-11 ), 7.07-7.12 (2H, m H-3',5'), 4.50 (1H, s, H-5); 13C NMR (100 MHz, 
DMSO) δC 162.3 (C-4), 160.1 (d, J = 243.8 Hz, C-2'), 157.9 (C-7), 152.6 (C-8), 149.5 (C-2), 
130.6 (d, J = 11.8 Hz, CH, C-4'), 129.8 (d, J = 3.8 Hz, C-1'), 128.7 (d, J = 8.4 Hz, CH, C-6'), 
124.4 (d, J = 3.0 Hz, CH, C-5'),  118.9 (C-10), 115.3 (d, J = 21.7 Hz, CH, C-3'), 87.2 (C-9), 
57.3 (C-6), 30.6 (CH, C-5); EIMS (m/z, rel. int.):  300 (M+) (25), 281 (35), 226 (35), 207 
(100), 167 (40), 159 (42); Anal. calc. for CHN: C: 56.00, H: 3.02, N: 18.66, Found: C: 56.10, 
H: 2.97, N: 18.02.  
(9) 7-amino-5-(3-fluorophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione, 
white powder; (96% yield); mp 224-226 ºC; UV λmax (DMSO) nm (log ϵ) 270 (2.93);   IR 
(KBr) υmax:  3376 (NH), 3186 (NH), 2197 (CN), 1717 (C=O), 1674 (C=O) cm-1; 1H NMR 
(400 MHz, DMSO) δH  12.06 (brs, NH), 11.06 (s, NH), 7.30-7.36 (1H, m, H-5'), 7.14 (s, 
NH2), 7.01-7.07 (3H, m H-2',4',6'), 4.27 (1H, s, H-5); 13C NMR (100 MHz, DMSO) δC 162.4 
(C-4), 162.1 (d, J = 241.9 Hz, C-3'), 157.6 (C-7), 152.4 (C-8), 149.5 (C-2), 147.0 (d, J = 6.3 
Hz, C-1'), 130.1 (d, J = 8.1 Hz, CH, C-5'), 123.4 (CH, C-6'), 119.0 (C-10), 114.0 (d, J = 21.5 
Hz, CH, C-2'),  113.5 (d, J = 20.9 Hz, CH, C-4'),  87.8 (C-9),  58.2 (C-6), 35.4 (CH, C-5);  
EIMS (m/z, rel. int.):  300 (M+) (18),  281 (41), 207 (100), 172 (74);  Anal. calc. for CHN: C: 
56.00, H: 3.02, N: 18.66,  Found: C: 55.97, H: 2.85, N: 18.39. 
(10)  7-amino-5-(4-fluorophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione, 
white powder,  (92% yield);  mp 228-230 ºC; UV λmax (DMSO) nm (log ϵ) 260 (2.93);    IR 
(KBr) υmax:  3194 (NH), 2197 (CN), 1723 (C=O), 1677 (C=O) cm-1; 1H NMR (400 MHz, 
DMSO) δH 12.06 (brs, NH), 11.05 (s, NH), 7.25 (2H, dd, J = 8.6, 5.6 Hz, H-2',6'), 7.10 (2H, 
dd, J = 8.6, 8.6 Hz, H-3',5'), 7.10 (s, NH), 4.26 (1H, s, H-5); 13C NMR (100 MHz, DMSO) δC 
162.4 (C-4), 161.0 (d, J = 240.8 Hz, C-4'), 157.5 (C-7), 152.2 (C-8), 149.5 (C-2), 140.1 (d, J 
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= 2.8 Hz, C-1'), 129.1 (d, J = 8.1 Hz, 2CH, C-2',6'), 119.1 (C-10), 114.8 (d, J = 21.2 Hz, 
2CH, C-3',5'),  88.3 (C-9),  58.7 (C-6), 35.0 (CH, C-5); EIMS (m/z, rel. int.):  300 (M+) (10), 
281 (13), 266 (19), 233 (19), 207 (100); Anal. calc. for CHN:  C: 56.00, H: 3.02, N: 18.66, 
Found C: 56.22, H: 2.65, N: 18.14. 
(11)  7-amino-5-(2,4-difluorophenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-
dione, white powder; (92% yield); mp 250-252 ºC; UV λmax (DMSO) nm (log ϵ) 265 (2.98); 
IR (KBr) υmax:  3395 (NH), 3306 (NH), 2195 (CN), 1718 (C=O), 1674 (C=O) cm-1; 1H NMR 
(400 MHz, DMSO) δH 12.10 (brs, NH), 11.08 (s, NH), 7.32 (ddd, J = 8.6, 8.6, 6.3, H-6'), 7.15 
(1H, ddd, J = 11.8, 9.4, 2.6, H-3'), 6.99 (1H, ddd, J = 8.4, 8.4, 2.4 Hz, H-5'), 7.18 (s, NH2), 
4.49 (s, H-5); 13C NMR (100 MHz, DMSO) δC 162.3 (C-4), 161.1 (dd, J = 243.0, 12.4 Hz, C-
2'*), 160.1 (dd, J = 246.5, 12.3 Hz, C-4'*), 157.9 (C-7), 152.6 (C-8), 149.5 (C-2), 131.1(dd, J 
= 9.6, 5.6 Hz, C-6'), 127.1 (dd, J = 12.3, 3.6 Hz, C-1'), 118.9 (C-10), 111.4 (d, J = 20.8 Hz, 
CH, C-5'), 103.6 (t, J = 25.9 Hz, CH, C-3') 87.0 (C-9),  57.0 (C-6), 29.6 (CH, C-5);  EIMS 
(m/z, rel. int.):  318 (M+) (15), 207 (100);  Anal. calc. for CHN: C: 52.84, H: 2.53, N: 17.61, 
Found: C: 51.98, H: 2.39, N: 17.47.  * assignments can be interchanged. 
 
Antibacterial Assay 
The antimicrobial activity of the synthesized compounds (1-11) were tested against the Gram 
+ve Staphylococcus aureus  ATCC 25923 and methicillin resistant S. aureus ATCC BAA-
1683 (MRSA), and three Gram -ve strains, Escherichia coli ATCC 25922, Pseudomonas 
aeruginosa ATCC 27853 and Klebsiella pneumonia ATCC 314588.  The standard antibiotics 
ciprofloxacin and ampicillin were used as controls for comparison.   
 
Mueller Hilton agar (Biolab, South Africa) was prepared (38 g in 1 L of water), poured into 
sterile pre-labelled petri dishes and allowed to set and dry at room temperature.  Bacterial 
66 
cultures were standardized using a 0.5 McFarland standard turbidity and swabbed onto agar 
plates.  Paper discs were loaded with 20 µL of the synthesised compounds and placed onto 
the prepared agar plates, inverted and incubated at 35-37°C for 24 hours.  The diameter of the 
zone of inhibition was measured in mm.   Compounds showing an inhibition zones of > 9 
mm were selected to determine their minimum bactericidal concentration (MBC) values 
using the broth dilution assay with ampicillin and ciprofloxacin as the controls following the 
method in Andrews (2001). Compounds 2-5, 8 and 11 showed zones of inhibition of > 9 mm 
and were tested further. 
 
To calculate the MBC values, the compounds were dissolved in DMSO (4.0 mg mL-1) and 
serially diluted in Mueller-Hinton broth (Oxoid, England) in Eppendorf tubes.  Each 
Eppendorf containing 180 µL of compound at different concentrations was inoculated with 
20 µL of the respective bacterial cultures and incubated at 37 oC for 18 hours. This was 
performed in duplicate.  Thereafter, 10 µL from each concentration was spotted onto 
Mueller-Hinton plates and incubated at 37 oC for 18 hours to determine the MBC. The MBC 
was the lowest concentration which showed no bacterial growth in the area in which the 
sample was placed.   
 
Cytotoxicity tests by the MTT assay 
Human cervical cancer (HeLa) cells were purchased from Highveld Biological (Pty) Ltd. 
(Lyndhurst, RSA). Cells were grown to semi-confluency in 25 cm2 tissue culture flasks in 
EMEM (Eagle's Minimum Essential Medium, Lonza BioWhittaker, Verviers, Belgium) 
supplemented with 10% fetal bovine serum and antibiotics (100 U mL-1 penicillin, 100 µg 
mL-1 streptomycin). For the MTT assay, cells were seeded at a density of 1.8 x103 cells per 
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well in a 96 well plate containing 100 µL of medium. The cells were then incubated for 24 h 
at 37oC in 5% CO2, after which the medium was removed and 100 µL fresh medium added.  
 
Compounds 1-11 (initially dissolved in DMSO at a concentration of 1 mg mL-1) were then 
added in triplicate to the cells (containing 100 µL of fresh medium) to a final concentration of 
10, 25, 50 and 100 µg mL-1 and incubated for 48 h at 37 oC. 5FU was used as a standard 
positive control.   
 
The MTT assay was adapted from Mosmann et al. (1983) and measures the metabolic 
activity of cells by the reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to formazan using the succinate-tetrazolium reductase system. 
After 48 h of incubation, the spent medium was replaced with 100 µL fresh medium and 100 
µL of MTT (5 mg mL-1 in PBS), and cells were incubated for 4 h at 37oC. Thereafter, the 
medium and MTT were removed, and 200 µL of DMSO was added to each well to dissolve 
the formazan salt. The absorbance of the resulting purple solution was read on a Mindray 
96A microplate reader (Vacutec, Hamburg, Germany) at 570 nm (detection l) and 630 nm 
(reference l for nonspecific signals) wavelengths. Cell viability (%) was directly correlated to 
absorbance and calculated in comparison to the untreated control as follows: 
[(OD570Treated - OD630Treated) / (OD570Control - OD630Control) x 100)] 
Tests were conducted in triplicate and the IC50 values (concentration at which 50% cell death 
was achieved) were determined using Microsoft Excel 2010™. 
 
Molecular Docking 
Different isomers of the representative compounds at physiological pH were generated using 
“Prepare Ligands” and energetically minimized in DS using CHARMm force field. The 
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isomer with the lowest CHARMm energy was selected for docking. The crystal structure of 
Human EG5 protein (pdb id: 2X7C) was downloaded from the protein data bank 
(http://www.rcsb.org). Only the B-chain of protein was considered while the native ligand, 
(s)-Enastron (KZ91367) and associated water molecules were removed. Initially, the 
protonation state of the protein was determined at physiological pH followed by its 
minimization. The “Prepare Protein” module in DS was used to build any missing 
loops/chains and determine the protonation state of each amino acid of the protein. 
 
The shake algorithm was used to constrain the hydrogen atoms of the protein during 
minimization. Before docking, a binding sphere (diameter 6.34 Å) with co-ordinates 16.8 
(X), 14.4 (Y) and -30.9 (Z), was generated using DS.  Docking simulations were conducted 
using the CDocker docking program (Wu et al., 2003) by keeping the position of protein 
fixed while allowing the ligand to flex. A total of 10 poses were generated for each 
compound and ranked according to the scoring function (-CDocker energy). The best pose 
was selected for binding energy calculations. 
 
3.4 Conclusion 
An environmentally friendly synthesis of pyrano [2,3-d] pyrimidinone derivatives in a one 
pot reaction using an organic catalyst, DABCO, which has the advantage of mild reaction 
conditions producing high yields of the final product (>90%) was reported.  The synthesized 
compounds showed good anticancer activity against HeLa cells.  The most active compounds 
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Chapter 4. Synthesis, molecular docking and anticancer activity of 5,5'-
(phenylmethylene)bis(6-amino-2-thiouracil) derivatives 
 
* The compounds referred to in this chapter are referred to in the abstract, conclusion and appendices or 
elsewhere in the thesis with a C preceding the number of the compound.  For example, 1 and 2 are referred to as 
C1 and C2 elsewhere in the thesis. 
 
ABSRACT 
A series of 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) derivatives (1-13) were 
synthesized by the condensation of 6-amino-2-thiouracil and benzaldehydes derivatives under 
reflux in glacial acetic acid. Nine compounds (3, 5 and 7-13) were novel.  Good binding 
affinity (BE) in the active site of Eg5 was shown by all compounds, which ranged between -
5.0 kcal mol-1 to -26.7 kcal mol-1.  Most compounds in the series exhibited stronger 
interaction than 5-FU (BE = -8.0 kcal mol-1) with Eg5.   The docking results were supported 
by cytotoxicity studies of the synthesized compounds against HeLa (cervical cancer) cell 
lines, where all compounds exhibited better anti-cancer activity than 5-fluorouracil (IC50 = 
12.08 µg mL-1) at the lowest concentration (10 µg mL-1) with IC50 values ranging from 4.18 
to 10.20 µg mL-1. 
 




5-Fluorouracil (5-FU) is a well-known anticancer drug used since the last century for the 
treatment of colon, breast and skin cancer either alone or in combination with other drugs 
(Diaso and Harris, 1989).    In the last few decades, it has been the major chemotherapeutic 
treatment for colorectal carcinoma (Adjei, 1999).  It is incorporated into RNA leading to 
interferences with maturation of RNA (Pinedo and Peters, 1988).  Thiouracils or 
mercaptouracil derivatives have also been known to possess good bioactivities, showing 
antiplatelet aggregating activity, anti-inflammatory, antiarrhythmic and antihyperlipidemic 
activity (Ranise et al., 1994). Pyrimidine thioethers have also shown to be HIV-1 reverse 
transcriptase inhibitors (Nugent et al., 1998; Navrotskii, 2005; Li et al., 2010; Wu et al., 
2013).  Fused uracil derivatives synthesized in a one-pot reaction also demonstrated binding, 
chelation and fragmentation of DNA (Mousa et al., 2012; 2015).  
 
6-Aminouracils and 6-amino-2-thiouracils (6-amino-2-thioxo-2,3-dihydropyrimidin-4(1H)-
one) are generally the precursors for the synthesis of pyridodipyrimidines, usually formed by 
the formylation of uracil precursors (Youssif et al., 1999; Shaker et al., 2009; Mousa et al., 
2012; Abdel-Aziem et al., 2012; Bhat and Dongre, 2015).  Youssif et al. (2003) reports the 
synthesis of (methylene)bis(6-amino-2-thiouracil) derivatives as an intermediate prior to the 
formation of the dipyrimidinopyrimidines, which was carried out with glacial acetic acid and 
a catalytic amount of hydrochloric acid.  Quinolines such as 7-chloro-5,8-quinolinedione was 
also reacted with 2,6-diamino-5-mercapto-4(3H)-pyrimidinone, similar to 6-amino-2-
thiouracil to synthesise triazaphenothiazine derivatives (Ezema, 2009).  Furochromone 
pyrimidine derivatives with anti-inflammatory and analgesic activity were also prepared by 
the reaction of furochromones with 6-amino-2-thiouracil (Abu-Hashem et al., 2011). 
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The synthesis of 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) was first reported in 1966 
by Pfleiderer and co-workers (Pfleiderer et al., 1966) by condensing 6-amino-2-thiouracil 
with benzaldehydes under reflux conditions.  The 4-methyl, 4-chloro and 4-fluorophenyl 
derivatives of 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) were prepared by chance on 
investigating the reaction of 6-amino-2-thiouracil with chalcones to produce pyrido[2,3-
d]pyrimidine derivatives (Chebanov et al., 2005).  Instead of using the chalcones themselves, 
they decided to use the chalcone precursors, benzaldehydes and acetophenone with 6-amino-
2-thiouracil and found that condensation took place with benzaldehydes only and that 
acetophenone took no part in the reaction.  In addition, El-kalyoubi et al. (2015) synthesised 
the 4-chloro, 3-nitro, 4-nitro, 4-bromo and 2-hydroxyphenyl derivatives of 5,5'-
(phenylmethylene)bis(6-amino-2-thiouracil) in a similar way before forming the 
pyridodipyrimidines by reflux with acetic acid and HCl under reflux.  They also report that 
the pyridodipyrimidines form without the isolation of the methylene bis(thiouracils) with 
longer reflux times.   
 
To the best of our knowledge, 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) has not been 
investigated for their anticancer activity.  We therefore carried out a simple condensation 
reaction of various substituted benzaldehydes with 6-amino-2-thiouracils under reflux to form 
the titled compounds and test them for their anticancer activity. 
 
4.2 Results and Discussion 
Synthesis 
Thirteen 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) derivatives (1-13) were 
synthesized from 6-amino-2-thiouracil and substituted benzaldehydes in the presence of an 
acetic acid catalyst in yields of between 68-96% after a 4 hour reflux (Figure 4-1).  Nine of 
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the compounds (3, 5 and 7-13) were to the best of our knowledge novel.  The structures of the 
synthesized compounds were confirmed by 1H and 13C NMR spectroscopy.  Compounds 2 
and 4, the 2-chloro and 2,4-dichloro derivatives are commercially available and 1 and 6, the 
unsubstituted and the 4-fluoro derivative were previously reported (Pfleiderer et al., 1966; 
Chebanov et al., 2005). 
 
Acetic acid was used in the reaction to activate the benzaldehydes in the reaction before it 
was attacked by the electrons from the double bond in 6-amino-2-thiouracil, forming a 
hydroxy intermediate (I).  Elimination of water then occurs, probably due to the conjugated 
system that results when water is eliminated resulting in (II).  A second molecule of 6-amino-
2-thiouracil then adds to the olefinic carbon in II, by a Michael addition, resulting in a 5,5'-
(phenylmethylene)bis(6-amino-2-thiouracil) after abstraction of a proton from III by the 
acetate ion (Figure 4-2). 
 
 




Figure 4-2  Plausible mechanism for the formation of 5,5'-(phenylmethylene)bis(6-amino-2-
thiouracil) derivatives (1-13) 
 
The structures of the novel compounds were elucidated using 1D 1H, 13C and 2D NMR 
spectroscopy along with mass spectrometry. Condensation of two molecules of 6-amino-2-
thiouracil with benzaldeyde was indicated by HMBC correlations between H-8 (occurring as 
a singlet at δ 5.34 in 1) and C-4/4' (δ 162.9), C-5/5' (δ 90.2), C-6/6' (δ 153.4), C-1'' (δ 137.9) 
and C-2''/6'' (δ 126.4).  The NH protons in 2-thiouracil occurred as a sharp singlet at δ 12.03 
and broad singlet at δ 11.82, each integrating to two protons relative to the H-8 resonance.  
The resonances of the NH2 groups occurred at δ 6.77 as a broad singlet and the resonances of 
the phenyl ring appeared between δ 7.06 and δ 7.24. 
 
77 
Molecular docking  
Human Kinesin Eg5, a member of the kinesin superfamily, plays an important role in cellular 
mitotic spindle formation (Blangy et al., 1995). The inhibition of this protein has been 
reported to cause arrest of cells in mitosis and thus serves as an excellent target for the 
discovery of new cancer chemotherapeutics. The efficiency of the docking protocol was 
checked by redocking the X-ray bound drug (KZ91367) into the binding site of Eg5, using 
the CDocker docking algorithm (Wu et al., 2003) embedded in Discovery Studio (DS). The 
results obtained revealed the interaction of the ligand with similar amino acids (Glu118, 
Gly117, Pro137 and Ala133) as observed in the X-ray structure. The computed all atoms root 
mean square deviation (RMSD) between the predicted ligand pose and its X-ray structure 
was found to be 0.76 Å (Figure 4-3), validating the accuracy of the docking method.   
 
All the synthesized compounds (1-13) were subsequently docked into the binding site of Eg5 
using the same docking procedure. The predicted binding affinity (BE) data for compounds 
1-13 ranged between -5.0 kcal mol-1 to -26.7 kcal mol-1 (Table 4-1), indicating good affinity 
by all compounds in the active site of Eg5.  In addition, a good correlation between the 
predicted BEs and experimental biological activity data was observed.  With the exception of 
9, all compounds of the series exhibited stronger interaction than 5-FU (BE = -8.0 kcal mol-1) 
with Eg5.  
 
The complexes of the two most potent compounds (4 and 7) with Eg5 were subsequently 
visualized (Figure 4-4 and Figure 4-5) in order to get a deeper understanding of their 
binding modes in the active site of the protein.  It could be seen that both the compounds 
interacted with almost similar amino acid residues of Eg5 through hydrogen bonding and 
electrostatic and hydrophobic modes of interaction. Compound 7 (2,4-difluoro derivative), 
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the most active compound, penetrated deep into the active site of Eg5 (Figure 4-6), and 
exhibited a hydrogen bond (2.7 Å) with Gly117 through its nitrogen atom (NH2 group) in 
addition to two electrostatic interactions with Arg119 and Glu116. Additionally, hydrogen 
bond interactions (non-conventional) with Pro137, Glu215 and Glu116 were also observed 




Figure 4-3  Overlay of the predicted pose of the native ligand, KZ91367 (light blue) obtained 






Figure 4-4  Complex showing important interactions of Eg5 amino acid residues (line 
format) with 7 (blue sticks). Hydrogen bonds (conventional – green; non-conventional - 
grey), electrostatic (gold) and hydrophobic (black) interactions are depicted. 
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Compound 4 (2,4-dichloro derivative) interacted in a similar fashion with Eg5 showing two 
concurrent hydrogen bonds (2.5 and 2.8 Å) through its amine (NH2) functionalities as 
depicted in Figure 4-5. In addition, hydrophobic (Leu160, Leu214, Ala218, Arg119 and 





Figure 4-5  Complex showing important interactions of Eg5 amino acid residues (line 
format) with 4 (blue sticks).  Hydrogen bonds (green dashed lines), electrostatic (golden 
dashed) and hydrophobic interactions (black dashed) are depicted. 
 
 
Figure 4-6  Surface representation of Eg5 showing deep penetration of 7 (green sticks) into 
the binding site cavity (pink sphere). 
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Anticancer activity 
Based on the predicted results from molecular docking, the synthesized compound were 
tested for their anticancer activity against a cervical cancerous cell line (HeLa) using the 
MTT assay.  The in vitro cytotoxicity levels of compounds 1-13 using HeLa cells are 
summarized in Table 4-1. The results indicated that almost all compounds were active at the 
lowest concentration (10 µg mL-1), with equally low IC50 values, ranging from 4.18 to 10.20 
µg mL-1, however no real trend was seen between concentration and activity. All 13 
compounds showed better IC50 values compared to 5FU (12.08 µg mL-1) and can be 
considered lead compounds in cancer treatment.  Further studies and testing of high activity 
compounds are hence warranted.  
 
Table 4-1 Viabilities (%) of the HeLa cell lines at different concentration of compounds 1-13 
including their binding affinity (BE) 






1 8.28±0.04a 23.12±0.13b,c 24.12±0.08c 19.7±0.11b 5.83 15.58 -26.7 
2 13.89±0.12b,c 15.79±0.02c 9.9±0.05a 11.56±0.10a,b 6.50 15.93 -17.2 
3 24.93±0.05c 10.42±0.10b 2.24±0.04a 7.85±0.01b 7.80 19.12 -20.6 
4 11.23±0.10b 8.61±0.01a 31.78±0.27c 14.37±0.09b 4.89 11.10 -22.6 
5 5.85±0.05 8.04±0.07 6.57±0.03 7.14±0.02 7.23 18.44 -23.6 
6 64.3±0.19c 45.6±012a 42.6±0.33a 51.2±0.55b 10.20 26.02 -25.3 
7 10.7±0.06a,b 17.13±0.05c 6.28±0.11a 11.23±0.06b 4.18 10.20 -20.1 
8 16.79±0.17b 14.32±0.01a,b 10.99±0.03a 20.08±0.36c 8.20 18.55 -15.8 
9 9.37±0.03a 28.5±0.05c 24.45±0.02c 17.17±0.05b 5.83 12.73 -5.0 
10 34.68±0.21c 6.14±0.06a 4.71±0.03a 10.23±0.01b 7.17 17.66 -21.1 
11 14.61±0.05b 6.23±0.06a 12.75±0.05b 11.09±0.11b 5.83 13.43 -16.6 
12 22.93±0.18b 12.94±0.03a 16.41±0.03a 13.32±0.11a 6.50 15.48 -22.9 
13 31.59±0.05c 13.32±010b 6.28±0.04a 11.85±0.06b 5.17 11.26 -12.4 
5FU 74.46±0.04a 71.360.08a 73.92±0.07a 78.63±0.02b 12.08 92.81 -8.0 
aBE = [(BEcomplex-BEligand+BEprotein)\ 
Data are presented as the mean ± SD values of triplicate determinations. a-c Different superscript letters for a 
given value within a column are significantly different from each other (Tukey’s-HSD multiple range post hoc 
test, p < 0.05). 
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4.3 Experimental  
General procedure for the synthesis of 5,5'(phenylmethylene)bis(6-amino-2-thiouracil) 
derivatives 
A solution of 6-amino-2-thiouracil (484 mg; 3.4 mmol) in glacial acetic acid (15 mL) and the 
appropriate aromatic aldehyde (1.5 mmol) was heated under reflux for 4 h. The reaction 
mixture was diluted with water and allowed to cool to room temperature. The crude product 
was filtered and recrystallized from ethanol to obtain the 5,5'-(phenylmethylene)bis(6-amino-
2-thiouracil) derivatives in yields of between 68-96%. 
 
(1) 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil), white powder (80% yield); mp 168-170 
ºC; IR (KBr) νmax: 3394 (NH), 3054, 2894, 1630 (C=O), 1597, 1548 cm-1;  1H NMR (400 
MHz, DMSO-d6) δH 12.03 (2H, bs, 2NH), 11.80 (2H, bs, 2NH), 7.21 (2H, t, J = 7.5 Hz, H-
3'',5''), 7.11 (1H, t, J = 7.5 Hz, H-4''), 7.07 (2H, d, J = 7.5 Hz, H-2'',6''), 6.76 (4H, bs, 2NH2), 
5.34 (1H, s, H-8); 13C NMR (100 MHz, DMSO-d6) δC  172.7 (2C, C-2,2'), 162.9 (2C, C-4,4'), 
153.4 (2C, C-6,6'), 137.9 (C-1''), 127.8 (2CH, C-3'',5''), 126.4 (2CH, C-2'',6''), 125.3 (CH, C-
4''), 90.2 (2C, C-5,5'), 32.4 (CH, C-8); HRMS (m/z): 373.0547 (M-H) (calculated for 
C15H13N6O2S2, 373.0541). 
(2) 5,5'-((2-chlorophenyl)methylene)bis(6-amino-2-thiouracil), white powder (78% yield); IR 
(KBr) νmax:  3484 (NH), 2879, 1636 (C=O), 1611, 1545 cm-1; 1H NMR (400 MHz, DMSO-d6) 
δH 12.02 (2H, bs, 2NH), 11.89 (2H, bs, 2NH), 7.16-7.31 (4H, m, H-3''-6''), 6.57 (4H, bs, 
2NH2), 5.30 (1H, s, H-8);  13C NMR (100 MHz, DMSO-d6) δC 172.7 (2C, C-2,2'), 162.5 (2C, 
C-4,4'), 153.1 (2C, C-6,6'), 136.9 (C-2''), 132.3 (C-1''), 129.5 (C-3''), 128.9 (C-5''), 127.5 (C-
4''), 126.6 (C-6''), 89.7 (2C, C-5,5'), 31.9 (CH, C-8); HRMS (m/z): 409.0300 (M+H) 
(calculated for C15H14ClN6O2S2, 409.0308). 
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(3) 5,5'-((3-chlorophenyl)methylene)bis(6-amino-2-thiouracil), white powder (83% yield); IR 
(KBr) νmax: 3397 (NH), 1635 (C=O), 1605 cm-1; 1H NMR (400 MHz, DMSO) δH 12.08 (2H, 
s, 2NH), 11.86 (2H, s, 2NH), 7.25 (1H, t, J = 7.8 Hz, H-5''), 7.18 (1H, d, J = 7.8 Hz, H-4''), 
7.07 (1H, s, H-2''), 7.06 (1H, d, J = 7.8 Hz, H-6''), 6.78 (4H, bs, 2NH2), 5.34 (1H, s, H-8); 13C 
NMR (100 MHz, DMSO) δC 172.8 (C-2/2'), 162.9 (C-4/4'), 153.4 (C-6/6'), 140.9 (C-1''), 
132.7 (C-3''),  129.6 (CH, C-5''), 126.3 (CH, C-2''), 125.4 (CH, C-4''), 125.3 (CH, C-6''), 89.7 
(C-5/5'), 32.3 (CH, C-8); HRMS (m/z): 409.0303 (M+H) (calculated for C15H14ClN6O2S2, 
409.0308). 
(4) 5,5'-((2,4-dichlorophenyl)methylene)bis(6-amino-2-thiouracil), white powder (96% 
yield); IR (KBr) νmax: 3383 (NH), 3358 (NH), 2877, 1649 (C=O), 1633, 1610, 1585, 1544 cm-
1; 1H NMR (400 MHz, DMSO-d6) δH 12.06 (2H, s, 2NH), 11.91 (2H, s, 2NH), 7.45 (1H, d, J 
= 2.1 Hz, H-3''), 7.31 (1H, dd, J = 8.5, 2.1 Hz, H-5''), 7.26 (1H, d, J = 8.5 Hz, H-6''), 6.55 
(4H, bs, 2NH2), 5.25 (1H, s, H-8); 13C NMR (100 MHz, DMSO) δC 172.7 (C-2/2'), 162.5 (C-
4/4'), 153.0 (C-6/6'), 136.3 (C-2''), 133.1 (C-4''), 131.1 (C-1''), 130.3 (CH, C-6''), 128.8 (CH, 
C-3''), 126.7 (CH, C-5''), 89.3 (C-5/5'), 31.6 (CH, C-8); HRMS (m/z): 442.9912 (M+H) 
(calculated for C15H13Cl2N6O2S2, 442.9918). 
(5) 5,5'-((3-fluorophenyl)methylene)bis(6-amino-2-thiouracil), white powder (92% yield); IR 
(KBr)  νmax: 3399 (NH), 2890, 1693 (C=O), 1605, 1555 cm-1; 1H NMR (400 MHz, DMSO-d6) 
δH 12.07 (2H, s, 2NH), 11.85 (2H, bs, 2NH), 7.27 (1H, ddd*, J = 7.9, 7.9, 7.9 Hz, H-5''), 6.94 
(1H, dd, J = 8.7, 2.0 Hz, H-2''), 6.92 (1H, d, J = 7.6 Hz, H-6''), 6.86 (1H, d, J = 11.0 Hz, H-
4''), 6.77 (4H, bs, 2NH2), 5.34 (1H, s, H-8);  13C NMR (100 MHz, DMSO) δC 172.8 (C-2/2'), 
162.4 (d, J = 242.6 Hz, C-3''), 162.9 (C-4/4'), 153.4 (C-6/6'), 141.4, (d, J = 7.1 Hz, C-1''), 
129.5 (CH, C-5''), 122.5 (CH, C-6''), 113.4, (CH, d, J = 21.4 Hz, C-4''), 112.2 (CH, d, J = 
20.9 Hz, C-2''),  89.9 (C-5/5'), 32.4 (CH, C-8); HRMS (m/z): 393.0603 (M+H) (calculated for 
C15H14FN6O2S2, 393.0604).  * resonance appears as a quartet due to signal overlap. 
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(6) 5,5'-((4-fluorophenyl)methylene)bis(6-amino-2-thiouracil), white powder (90% yield); IR 
(KBr) νmax: 3396 (NH), 1631 (C=O), 1601, 1550 cm-1;  1H NMR (400 MHz) δH 12.07 (2H, s, 
2NH), 11.84 (2H, s, 2NH), 7.08 (2H, dd, J = 8.5, 5.8 Hz, H-2''/6''), 7.02 (2H, t, J = 8.8 Hz, H-
3''/5''), 6.77 (4H, bs, 2NH2), 5.31 (1H, s, H-8);  13C NMR (100 MHz, DMSO) δC 173.3 (C-
2/2'), 163.4 (C-4/4'), 160.6 (d, J = 191.7 Hz, C-4''), 153.9 (C-6/6'), 134.4 (C-1''), 128.8 (2CH, 
d, J = 6.4 Hz, C-2''/6''), 114.8 (2CH, d,  J = 16.9 Hz, C-3''/5''), 90.7 (C-5/5'), 32.4 (CH, C-8); 
HRMS (m/z): 393.0598 (M+H) (calculated for C15H14FN6O2S2, 393.0604). 
(7) 5,5'-((2,4-difluorophenyl)methylene)bis(6-amino-2-thiouracil), white powder (86% 
yield); IR (KBr) νmax: 3385 (NH), 3052, 2897, 1634 (C=O), 1601, 1549 cm-1;  1H NMR (400 
MHz, DMSO-d6) δH 12.03 (2H, s, 2NH), 11.85 (2H, bs, 2NH), 7.12 (1H, ddd*, J = 8.9, 8.9, 
8.9 Hz, H-6''), 7.01 (1H, ddd, J = 11.5, 9.1, 2.5 Hz, H-3''), 6.91 (1H, td, J = 8.4, 2.4 Hz, H-
5''), 6.58 (4H, bs, 2NH2), 5.30 (1H, s, H-8); 13C NMR (100 MHz, DMSO) δC 172.7 (C-2/2'), 
162.7 (C-4/4'), 160.7 (dd, J = 242.6, 12.2 Hz, C-2''), 160.4 (dd, J = 246.7, 12.0 Hz, C-4''),  
152.8 (C-6/6'), 129.5 (CH, C-6''), 122.0 (dd, J = 12.5, 3.6 Hz, C-1''), 110.3 (CH, d, J = 20.7 
Hz, C-5''), 103.4 (CH, t,  J = 25.9 Hz, C-3''), 89.5 (C-5/5'), 28.2 (CH, C-8); A mass spectrum 
could not be detected for this molecule. 
(8) 5,5'-((4-trifluoromethylphenyl)methylene)bis(6-amino-2-thiouracil), white powder 
(84% yield); IR (KBr) νmax: 3396 (NH), 3052, 2896, 1634 (C=O), 1601, 1550;  1H NMR (400 
MHz, DMSO-d6) δH 12.09 (2H, s, 2NH), 11.88 (2H, s, 2NH), 7.56 (2H, d, J = 8.2 Hz, H-
3''/5''), 7.30 (d, J = 8.2 Hz, H-2''/6''), 6.77 (4H, bs, 2NH2), 5.40 (1H, s, H-8); 13C NMR (100 
MHz, DMSO) δC 172.9 (C-2/2'), 162.9 (C-4/4'), 153.4 (C-6/6'), 143.3 (C-1''), 127.4 (C-2''/6''), 
126.1 (q, J = 31.5 Hz, C-4''), 124.5 (q, J = 270.2 Hz, CF3), 124.6 (C-3''/5''), 89.7 (C-5/5'), 
32.6 (CH, C-8); HRMS (m/z): 443.0562 (M+H) (calculated for C16H14F3N6O2S2, 443.0572). 
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(9) 5,5'-((3-trifluoromethoxyphenyl)methylene)bis(6-amino-2-thiouracil), white powder 
(72% yield); IR (KBr) νmax: 3400 (NH), 2855, 1610, 1546 cm-1; 1H NMR (400 MHz, DMSO-
d6) δH 12.12 (2H, s, 2NH), 11.90 (2H, bs, 2NH), 7.39 (1H, t, J = 8.0 Hz, H-5''), 7.15 (2H, d*, 
J = 8.0 Hz, H-4''/6''), 7.04 (1H, s, H-2''), 6.81 (4H, bs, 2NH2), 5.40 (1H, s, H-8);  13C NMR 
(100 MHz, DMSO) δC 172.8 (C-2/2'), 172.0 (C-3''), 162.9 (C-4/4'), 153.4 (C-6/6'), 141.2 (C-
1''), 129.5 (CH, C-5''), 125.7 (CH, C-6''), 120.1 (q, J = 254.3 Hz, OCF3), 119.3 (CH, C-2''), 
117.7 (CH, C-4''), 89.7 (C-5/5'), 32.4 (CH, C-8);  HRMS (m/z): 457.0364 (M+-H) (calculated 
for C16H12F3N6O3S2, 457.0364).  *overlapping doublets. 
(10) 5,5'-((3,4-dihydroxyphenyl)methylene)bis(6-amino-2-thiouracil), yellow powder 
(92% yield); IR (KBr) νmax: 3171, 1650 (C=O), 1581, 1533 cm-1;  1H NMR (400 MHz, 
DMSO) δH 11.97 (2H, s, 2NH), 11.76 (2H, bs, 2NH), 8.59 (1H, s, 4'-OH), 8.42 (1H, s, 3'-
OH), 6.72 (4H, bs, 2NH2), 6.52  (1H, d, J = 8.2 Hz, H-5''), 6.43 (1H, d, J = 1.2 Hz, H-2''), 
6.26 (1H, dd, J = 8.2, 1.2 Hz, H-6''), 5.17 (1H, s, H-8);  13C NMR (100 MHz, DMSO) δC 
172.6 (C-2/2'), 162.9 (C-4/4'), 153.3 (C-6/6'), 144.7 (C-4''), 142.8 (C-3''), 128.4 (C-1''), 117.1 
(CH, C-6''), 115.1 (CH, C-5''), 113.9 (CH, C-2''), 90.7 (C-5/5'), 31.7 (CH, C-8);  HRMS 
(m/z): 407.0573 (M+H) (calculated for C15H15N6O4S2, 407.0596). 
(11) 5,5'-((2,4-dimethoxyphenyl)methylene)bis(6-amino-2-thiouracil), yellow powder 
(68% yield); IR (KBr) νmax: 3398 (NH), 3314 2885, 1634 (C=O), 1610, 1547 cm-1; 1H NMR 
(400 MHz, DMSO-d6) δH 11.90 (2H, s, 2NH), 11.77 (2H, bs, 2NH), 6.90 (1H, d, J = 8.4 Hz, 
H-6''), 6.51 (4H, bs, 2NH2), 6.42 (1H, d, J = 2.4 Hz, H-3''), 6.39 (1H, dd, J = 8.4, 2.4 Hz, H-
5''), 5.18 (1H, s, H-8), 3.71(3H, s, 2''-OCH3), 3.62 (3H, s, 4''-OCH3); 13C NMR (100 MHz, 
DMSO) δC 172.5 (C-2/2'), 162.7 (C-4/4'), 158.9 (C-2''), 158.2 (C-4''), 152.7 (C-6/6'), 127.8 
(CH, C-6''), 119.1 (C-1''), 104.0 (CH, C-5''), 98.4 (CH, C-3''), 91.1 (C-5/5'), 55.7 (2''-OCH3), 
55.1 (4''-OCH3),  28.7 (CH, C-8);  HRMS (m/z): 457.0721 (M+Na) (calculated for 
C17H18N6O4S2Na, 457.0729). 
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(12) 5,5'-((4-methylthiophenyl)methylene)bis(6-amino-2-thiouracil), yellow powder (89% 
yield); IR (KBr) νmax: 3393 (NH), 3060, 2895, 1632 (C=O), 1599, 1550 cm-1;  1H NMR (400 
MHz, DMSO-d6) δH 12.03 (2H, s, 2NH), 11.80 (2H, bs, 2NH), 7.10 (2H, d, J = 8.2 Hz, H-
3''/5''), 6.99 (2H, d, J = 8.2 Hz, H-2''/6''), 6.75 (4H, bs, 2NH2), 5.28 (1H, s, H-8), 2.41 (3H, s, 
S-CH3); 13C NMR (100 MHz, DMSO) δC 172.7 (C-2/2'), 162.9 (C-4/4'), 153.3 (C-6/6'), 134.8 
(C-1''), 134.3 (C-4''), 127.2 (2CH, C-2''/6''), 125.8 (2CH, C-3''/5''), 90.1 (C-5/5'), 31.8 (CH, C-
8), 15.0 (S-CH3); HRMS (m/z): 421.0571 (M+H) (calculated for C16H17N6O2S3, 421.0575). 
(13) 5,5'-((4-morpholinophenyl)methylene)bis(6-amino-2-thiouracil), yellow powder (90% 
yield); IR (KBr) νmax: 3422 (C=O), 3310, 3180, 2894, 1635 (C=O), 1539 cm-1; 1H NMR (400 
MHz, DMSO) δH 12.01 (2H, s, 2NH), 11.80 (2H, s, 2NH), 6.91 (2H, d, J = 8.5 Hz, H-2''/6''), 
6.80 (2H, d, J = 8.5 Hz, H-3''/5''), 6.79 (4H, bs, 2NH2), 5.27 (1H, s, H-8), 3.71  (4H, t, J = 4.4 
Hz, H-3'''/5'''), 3.03 (4H, t, J = 4.4 Hz, H-2'''/6''');  13C NMR (100 MHz, DMSO) δC 172.7 (C-
2/2'), 162.9 (C-4/4'), 153.3 (C-6/6'), 148.7 (C-4''), 128.4 (C-1''), 127.0 (2CH, C-2''/6''), 114.8 
(2CH, C-3''/5''), 90.5 (C-5/5'), 66.1 (C-3'''/5'''), 48.7 (C-2'''/6'''), 31.6 (CH, C-8); HRMS (m/z): 
482.1065 (M+Na) (calculated for C19H21N7O3S2Na, 482.1045). 
 
Cytotoxicity tests  
Human cervical cancer (HeLa) cells were purchased from Highveld Biological (Pty) Ltd. 
(Lyndhurst, RSA). Cells were grown to semi-confluency in 25 cm2 tissue culture flasks in 
EMEM (Eagle's Minimum Essential Medium, Lonza BioWhittaker, Verviers, Belgium) 
supplemented with 10% fetal bovine serum and antibiotics (100 U mL-1 penicillin, 100 µg 
mL-1 streptomycin). For the MTT assay, cells were seeded at a density of 1.8 x103 cells per 
well in a 96 well plate containing 100 µL of medium. The cells were then incubated for 24 h 
at 37oC in 5% CO2, after which the medium was removed and 100 µL fresh medium was 
added.  
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Compounds 1-13 at concentrations of 10 µg mL-1, 25 µg mL-1, 50 µg mL-1 and 100 µg mL-1, 
were then added in triplicate to the cells and incubated for 48 h at 37 oC. 5FU (5-fluorouracil) 
was used as a standard positive control. 
 
The MTT assay was adapted from that of Mosmann et al. (1983) and measured the metabolic 
activity of cells by the reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to formazan using the succinate-tetrazolium reductase system. 
After 48 h of incubation, the spent medium was replaced with 100 µL fresh medium and 100 
µL of MTT (5 mg mL-1 in PBS), and the cells incubated for 4 h at 37 oC. Thereafter, the 
medium and MTT were removed, and 200 µL of DMSO was added to each well to dissolve 
the formazan salt. The absorbance of the resulting purple solution was read in a Mindray 96A 
microplate reader (Vacutec, Hamburg, Germany) at 570 nm (detection l) and 630 nm 
(reference l for nonspecific signals) wavelengths. Cell viability (%) was directly correlated to 
absorbance and calculated in comparison to the untreated control as follows: 
[(OD570Treated - OD630Treated) / (OD570Control - OD630Control) x 100)] 
Tests were conducted in triplicate and calculation of the concentration at which 50% cell 
death was achieved (IC50) was carried out using Microsoft Excel 2010™. 
 
Molecular docking 
The atomic co-ordinates of Human EG5 protein (pdb id: 2X7C) were retrieved from the 
protein data bank (http://www.rcsb.org). All chains with the exception of the B-chain with the 
native ligand, (s)-Enastron (KZ91367) were removed using DS visualizer. Initially, the 
protonation state of protein was determined at physiological pH followed by its minimization 
using the conjugate gradient algorithm with the CHARMm force field, using the Prepare 
Protein algorithm in DS. All hydrogen atoms of the protein were constrained during the 
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minimization process by applying the shake algorithm. A sphere of diameter dimensions 6.34 
Å with co-ordinates 16.8 (X), 14.4 (Y) and -30.9 (Z), covering all the active site residues was 
generated using the Define and Edit Binding site module embedded in DS.  The 3D structure 
of each synthesized compound was subjected to “Prepare Ligands” in DS to generate its 
isomers at physiological pH. The isomers obtained were further minimized and the isomer 
with the lowest CHARMm energy selected for docking. The CDocker docking program 
available in DS was used to dock compounds in the binding site of the protein (Wu et al., 
2003). This program samples different conformations of the ligand during docking simulation 
by keeping the protein conformation fixed. A total of 10 poses of each ligand were ranked on 
the basis of their scoring function (-CDocker energy).  
 
4.4 Conclusion 
A series of 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) derivatives were synthesized in 
good yields from 6-amino-2-thiouracil and benzaldehyde derivatives.  All the synthesised 
compounds showed better activity than 5-FU in a cancerous HeLa cell line.  Molecular 
docking indicated that most compounds displayed stronger interactions than 5-FU with Eg5.  
This series of compounds may be good lead compounds in cancer therapy. 
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Chapter 5. Conclusion 
Two types of pyrimidine derivatives were successfully synthesised and characterised.  The 
first type was of the 7-amino-5-aryl-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-diones 
and the second was of the 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) type.  Various 
substituted aryl derivatives of 7-amino-5-aryl-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-
2,4-diones with hydroxy, methoxy, chloro, nitro and fluoro substituents on the phenyl ring 
were synthesised in excellent yields (90-96%) in a one-pot reaction from substituted aromatic 
benzaldehydes, malonitrile and barbituric acid using DABCO as a catalyst in aqueous ethanol 
in 1 hour at room temperature.  An investigation into several catalysts including DABCO, 
DBA, triethylamine, K2CO3 and L-proline indicated that DABCO was the best catalyst for 
the reaction.  This reaction using DABCO as a catalyst is therefore a fast, easy route for the 
synthesis of pyranopyrimidines from aldehydes, malonitrile and barbituric acid.  Variation 
can be introduced into the molecule using various substituted aldehydes and small libraries of 
these types of compounds can quickly be synthesised and tested for their bioactivity. 
 
A total of thirteen 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) derivatives were 
successfully synthesised by a condensation reaction between 6-amino-2-thiouracil and 
benzaldehyde derivatives in glacial acetic acid under reflux with yields of 68-96%.  The 
duration of the reaction was 4 hours.  There are variable reports in the literature which 
indicate that refluxing for 4-6 hours (El-kalyoubi et al., 2015) or 2-7 hours (Youssif and 
Mohamed, 2008) results in pyridodipyrimidines, however we did not synthesise 
pyridopyrimidines in our work.  This was confirmed by High Resolution Mass Spectroscopy.  
This method represents a relatively fast and easy method for condensing benzaldehydes and 
6-amino-2-thiouracils to form the target compounds.  The products must be characterised by 
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Mass spectrometry to detect whether or not the pyridopyrimidines or the 5,5'-
(phenylmethylene)bis(6-amino-2-thiouracil) derivatives formed. 
 
All the synthesised compounds were easily purified either by recrystallization or column 
chromatography and characterised by 1D and 2D NMR and Mass spectroscopy. A total of 12 
compounds, three from the pyranopyrimidine series (A3, A7 and B11) and 9 from the 5,5'-
(phenylmethylene)bis(6-amino-2-thiouracil) series (C3, C5 and C7-13) were novel 
derivatives. 
 
The synthesized compounds were tested for their antibacterial and anticancer activity since 
pyrimidines have been known to be active in antibacterial and anticancer assays.  The 
compounds were tested against five bacterial strains, two Gram +ve, Staphylococcus aureus 
and MRSA and three Gram –ve strains, Escherichia coli, Pseudomonas aeruginosa and 
Klebsiella pneumonia. The oxygenated pyranopyrimidines performed better in the 
antibacterial assays than the chloro, fluoro and nitro derivatives.  In particular, A6 (2',3'-
dimethoxy derivative) showed broad spectrum activity amongst the strains tested having IC50 
values of 45.6 µM and 91.3 µM against S. aureus and E. coli respectively.   The 5,5'-
(phenylmethylene)bis(6-amino-2-thiouracil) derivatives did not show any antibacterial 
activity in preliminary disk diffusion assays carried out.  The results indicated that even 
though A6 showed some good antibacterial activity, these classes of compounds in general 
were not suitable as antibacterial agents. 
 
In general, all the synthesised compounds showed good activity in the anticancer assays 
carried out.  This could be due to their structural similarity with known anticancer agents 
such as 5-FU, which was used as a standard for comparison in this work.  Compounds A1-A7 
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were tested against three cell lines, HeLa (cervical cancer), Caco-2 (colorectal 
adenocarcinoma) and HEK293 (human embryonic kidney).  All the compounds were 
comparable to 5-FU in all three cell lines, however three compounds, A2, A5 and A7 had 
IC50 values ten times lower than 5-FU in the HeLa cell line (3.46, 4.36 and 4.44 µM 
respectively opposed to 41.85 µM for 5-FU) and could be excellent lead compounds for 
anticancer treatment.  The other two sets of compounds, B1-11 and C1-13 were tested only in 
the HeLa cell line, since the first set of compounds were most active in this cell line.  The 
anticancer activity of B1-11 was comparable to 5-FU in the same assay and that of C1-13 was 
3-8 times better than 5-FU.  The three most active compounds of this series were the 2,4-
difluoro derivative (7) (IC50 10.20 µM), the 2,4-dichloro derivative (4) (IC50 11.10 µM) and 
the morpholine derivative (13) (IC50 11.26 µM).  Thus, the 5,5'-(phenylmethylene)bis(6-
amino-2-thiouracil) could also be good leads for anticancer treatment and need to be explored 
further. 
 
In order to provide a possible explanation for the anticancer activity shown by the 
pyrimidines synthesised in this work, two representative compounds from each of the series 
A and B, A1, A7, B4 and B8 were docked computationally into the active site of a human 
kinesin molecular motor protein essential in mitosis, Eg5.  This enzyme is a common target 
for anticancer treatment.  All four compounds had better calculated binding energies than 5-
FU (-180.25, -140.9, -184.4 and -150.1 kcal mol-1 respectively as opposed to -116.7 kcal mol-
1 for 5-FU).  For the 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) series C1-13, all 
compounds were docked with Eg5 computationally using an implicit solvent model.  All the 
compounds in this series, except for C-9 (-5.0 kcal mol-1) showed better binding energies 
than 5-FU (-8.0 kcal mol-1).  Their binding energies ranged from -12.4 to 26.7 kcal mol-1.  
The molecular docking studies thus indicate that a possible mechanism for the anticancer 
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activity could be due to the synthesised compounds binding with the Eg5 protein, altering its 
structure slightly, causing the enzyme to lose its function. 
 
Future Work 
There are three good leads for anticancer treatment from the first set of compounds A2, A5 
and A7 and all of 5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) derivatives C1-13 are also 
good leads for cancer therapy.  These compounds need to be explored further and tested in 
vivo to see whether or not they could be used in anticancer treatment.  They also need to be 
tested in other cancerous cell lines to see whether they can be used for the treatment of other 
cancerous cells as well. 
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13C NMR spectrum of 7-amino-5-(3-methoxyphenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-dione 
(A4)































































































































































































































































































































































































































































































































































































































































































































































































































Mass spectrum of 7-amino-5-(2,3-dimethoxyphenyl)-6-cyano-5H-pyrano[2,3-d]pyrimidin-(1H,3H)-2,4-
dione (A6)
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DEPT spectrum of  5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) (C1) 































IR spectrum of  5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) (C1) 
HRMS of  5,5'-(phenylmethylene)bis(6-amino-2-thiouracil) (C1) 





































1H NMR spectrum of  5,5'-((2-chlorophenyl)methylene)bis(6-amino-2-thiouracil) (C2) 
3’’/4’’/5’’/6’’
7/7’
1H NMR spectrum of  5,5'-((2-chlorophenyl)methylene)bis(6-amino-2-thiouracil) (C2) 
3’’/4’’/5’’/6’’






DEPT spectrum of  5,5'-((2-chlorophenyl)methylene)bis(6-amino-2-thiouracil) (C2) 





































IR spectrum of  5,5'-((2-chlorophenyl)methylene)bis(6-amino-2-thiouracil) (C2) 
HRMS of  5,5'-((2-chlorophenyl)methylene)bis(6-amino-2-thiouracil) (C2) 







































13C NMR spectrum of  5,5'-((3-chlorophenyl)methylene)bis(6-amino-2-thiouracil) (C3) 
2/2’
4/4’ 6/6’ 1’’ 3’’5’’
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DEPT spectrum of  5,5'-((3-chlorophenyl)methylene)bis(6-amino-2-thiouracil) (C3) 

































IR spectrum of  5,5'-((3-chlorophenyl)methylene)bis(6-amino-2-thiouracil) (C3) 
HRMS of  5,5'-((3-chlorophenyl)methylene)bis(6-amino-2-thiouracil) (C3) 


















































DEPT spectrum of  5,5'-((2,4-dichlorophenyl)methylene)bis(6-amino-2-thiouracil) (C4) 






























IR spectrum of  5,5'-((2,4-dichlorophenyl)methylene)bis(6-amino-2-thiouracil) (C4) 
HRMS of  5,5'-((2,4-dichlorophenyl)methylene)bis(6-amino-2-thiouracil) (C4) 


































1H NMR spectrum of  5,5'-((3-fluorophenyl)methylene)bis(6-amino-2-thiouracil) (C5) 
5’’
4’’/6’’/2’’








DEPT spectrum of  5,5'-((3-fluorophenyl)methylene)bis(6-amino-2-thiouracil) (C5) 


































IR spectrum of  5,5'-((3-fluorophenyl)methylene)bis(6-amino-2-thiouracil) (C5) 
HRMS spectrum of  5,5'-((3-fluorophenyl)methylene)bis(6-amino-2-thiouracil) (C5) 


































1H NMR spectrum of  5,5'-((4-fluorophenyl)methylene)bis(6-amino-2-thiouracil) (C6) expanded
2’’/6’’
3’’/5’’
13C NMR spectrum of  5,5'-((4-fluorophenyl)methylene)bis(6-amino-2-thiouracil) (C6)
2/2’
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5/5’ 8
13C NMR spectrum of  5,5'-((4-fluorophenyl)methylene)bis(6-amino-2-thiouracil) (C6)
2’’/6’’ 3’’/5’’
DEPT spectrum of  5,5'-((4-fluorophenyl)methylene)bis(6-amino-2-thiouracil) (C6)



































IR spectrum of  5,5'-((4-fluorophenyl)methylene)bis(6-amino-2-thiouracil) (C6)
HRMS of  5,5'-((4-fluorophenyl)methylene)bis(6-amino-2-thiouracil) (C6)







































1H NMR spectrum of  5,5'-((2,4-difluorophenyl)methylene)bis(6-amino-2-thiouracil) (C7)
6’’
3’’ 5’




6’’ 1’’ 5’’ 3’’
5/5’
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13C NMR spectrum of  5,5'-((2,4-difluorophenyl)methylene)bis(6-amino-2-thiouracil) (C7)
2’’-F
4’’-F
13C NMR spectrum of 5,5'-((2,4-difluorophenyl)methylene)bis(6-amino-2-thiouracil) (C7) expanded
1’’ 5’’
3’’
DEPT spectrum of  5,5'-((2,4-difluorophenyl)methylene)bis(6-amino-2-thiouracil) (C7)




































IR spectrum of  5,5'-((2,4-difluorophenyl)methylene)bis(6-amino-2-thiouracil) (C7)
















































DEPT spectrum of  5,5'-((4-trifluoromethylphenyl)methylene)bis(6-amino-2-thiouracil) (C8)




























IR spectrum of  5,5'-((4-trifluoromethylphenyl)methylene)bis(6-amino-2-thiouracil) (C8)
HRMS of  5,5'-((4-trifluoromethylphenyl)methylene)bis(6-amino-2-thiouracil) (C8)



































1H NMR spectrum of  5,5'-((4-trifluoromethoxylphenyl)methylene)bis(6-amino-2-thiouracil) (C9) expanded
5’’ 4’’/6’’
2’’







DEPT spectrum of  5,5'-((4-trifluoromethoxylphenyl)methylene)bis(6-amino-2-thiouracil) (C9)
HSQC spectrum of  5,5'-((4-trifluoromethoxylphenyl)methylene)bis(6-amino-2-thiouracil) (C9)






























IR spectrum of  5,5'-((4-trifluoromethoxylphenyl)methylene)bis(6-amino-2-thiouracil) (C9)
HRMS of  5,5'-((4-trifluoromethoxylphenyl)methylene)bis(6-amino-2-thiouracil) (C9)



















































DEPT spectrum of  5,5'-((3,4-dihydroxylphenyl)methylene)bis(6-amino-2-thiouracil) (C10)





































IR spectrum of  5,5'-((3,4-dihydroxylphenyl)methylene)bis(6-amino-2-thiouracil) (C10)
HRMS of  5,5'-((3,4-dihydroxylphenyl)methylene)bis(6-amino-2-thiouracil) (C10)



















































DEPT 90 spectrum of  5,5'-((2,4-dimethoxylphenyl)methylene)bis(6-amino-2-thiouracil) (C11)
6’’ 5’’ 3’’ 8
DEPT 135 spectrum of  5,5'-((2,4-dimethoxylphenyl)methylene)bis(6-amino-2-thiouracil) (C11)
2’’’ 4’’’

































IR spectrum of  5,5'-((2,4-dimethoxylphenyl)methylene)bis(6-amino-2-thiouracil) (C11)
HRMS of  5,5'-((2,4-dimethoxylphenyl)methylene)bis(6-amino-2-thiouracil) (C11)











































DEPT spectrum of  5,5'-((4-methylthiolphenyl)methylene)bis(6-amino-2-thiouracil) (C12)

































IR spectrum of  5,5'-((4-methylthiolphenyl)methylene)bis(6-amino-2-thiouracil) (C12)
HRMS of  5,5'-((4-methylthiolphenyl)methylene)bis(6-amino-2-thiouracil) (C12)












































1H NMR spectrum of  5,5'-((4-morpholinylphenyl)methylene)bis(6-amino-2-thiouracil) (C13) expanded
2’’/6’’ 3’’/5’’
13C NMR spectrum of  5,5'-((4-morpholinylphenyl)methylene)bis(6-amino-2-thiouracil) (C13)
2/2’





DEPT spectrum of  5,5'-((4-morpholinylphenyl)methylene)bis(6-amino-2-thiouracil) (C13)





































IR spectrum of  5,5'-((4-morpholinylphenyl)methylene)bis(6-amino-2-thiouracil) (C13)
HRMS of  5,5'-((4-morpholinylphenyl)methylene)bis(6-amino-2-thiouracil) (C13)
UV spectrum of  5,5'-((4-morpholinylphenyl)methylene)bis(6-amino-2-thiouracil) (C13)
